Spenser Lin No Comments

Healthcare News, Deals, and Investments Update October 5th, 2026

LECO_Weekly-Healthcare-News_10-05-2026Download

Healthcare Weekly News and Deals – Oct 5th, 2026

  1. Smart ring maker Oura has postponed its Nasdaq IPO, which would have raised up to $2.2 billion through the sale of 50 million shares, citing uncertainty in the listing market just eight days after formally launching the process. Oura delayed its planned Nasdaq listing despite what it described as strong demand and a strengthening of the business since the IPO process began. The company launched its plans on September 21 and had intended to raise up to $2.2 billion by selling 50 million shares. CEO Tom Hale said Oura aims to deliver an extraordinary IPO for employees and investors and has “the luxury of choosing our moment.” Oura says it is profitable, with revenue expected to grow 90% year over year in fiscal 2026. It follows Holtec Nuclear’s withdrawal earlier in the month. (Link)
  2. U.S. healthcare technology investor Thoreau has committed $500 million to launch Ortet, a frontier AI lab for health building models that connect patient biology, treatment and healthcare administration. Ortet launched on September 29, 2026 with a $500 million commitment from Thoreau, bringing together former drug industry and technology company researchers. The company plans to use the backing to build computing and data infrastructure, train and deploy health-focused models, and recruit researchers and engineers. Ortet has already secured an initial cluster of graphics processing units, the specialized chips used to train and run AI systems. Rather than targeting a single clinical task, the lab is building models intended to link patient biology, treatment and healthcare administration, making it one of the largest single capital commitments to a healthcare AI company at formation. (Link)
  3. Grindr (NYSE:GRND) has agreed to acquire PurposeMed, the parent company of HIV-prevention telehealth provider Freddie, in a $250 million cash-and-stock deal with up to $70 million of additional performance consideration. Grindr will pay $190 million in cash and $60 million in common stock for PurposeMed, with up to $70 million in further cash tied to Freddie’s 2027 performance and payable in 2028. The transaction is expected to close in the fourth quarter and is Grindr’s first major acquisition since its 2009 founding. CEO George Arison said the healthcare line could become as profitable and as large as the core business, and that building it internally would have taken two to three years. Grindr expects the combined U.S. telehealth and pharmacy business to generate more than $400 in monthly revenue per active patient, implying roughly $240 million of annual revenue at 50,000 patients. (Link)
  4. Inogen (NASD: INGN) has agreed to divest its U.S. oxygen rental business to national home respiratory provider Rotech Healthcare for estimated cash consideration of up to $25 million. Inogen (INGN) signed a definitive agreement to sell specified U.S. oxygen rental assets to Rotech Healthcare for total estimated cash consideration of up to $25 million, with closing expected in the fourth quarter of 2026. The rental business generated $24.3 million of revenue in the first half of 2026, a 9.8% year-over-year decline, and will be presented as discontinued operations beginning in Q3. Inogen expects the transactions to increase both its revenue growth rate and adjusted operating income. Subject to closing, the board approved a $15 million increase to the share repurchase authorization, taking it to $45 million through June 2028. (Link)
  5. Interpace Biosciences (IDXG) has filed terms for a $20 million offering of 3.1 million shares at an assumed $6.47 per share to support a proposed uplisting from OTC to Nasdaq. Interpace Biosciences (IDXG), the Parsippany, New Jersey molecular diagnostics company behind the ThyGeNEXT and ThyraMIR v2 thyroid tests, filed terms on September 25, 2026 for a $20 million deal covering 3.1 million shares at an assumed $6.47; the offering remains unpriced. The raise follows an August reverse stock split announced to support the proposed Nasdaq uplisting. Thyroid test volume rose from 25,200 in 2022 to 36,200 in 2025 and pro forma revenue grew from $20.3 million to $34.8 million, a 19.7% CAGR, after the company stopped accepting PancraGEN specimens in May 2025 following a loss of CMS reimbursement. (Link)
  6. KALA Bio (NASD: KALA) has signed a non-binding letter of intent to acquire 100% of a privately held U.S. telehealth management services organization for approximately $15 million in cash and KALA stock. KALA Bio (KALA) signed the LOI on September 24, 2026 for an MSO supporting a LegitScript-certified, NABP-accredited provider-led telehealth platform operating in all 50 states across GLP-1 weight management, hormone health, longevity and sexual wellness. The target generated roughly $12.7 million of unaudited revenue for the trailing twelve months ended August 2026, over $48 million of sales since its 2023 founding, has served more than 90,000 clients and is described as cash-flow positive. The cash portion would come from existing balance sheet resources, with closing targeted for late 2026 or early 2027. (Link)
  7. SpyGlass Pharma (NASD: SGP) has acquired Advanced Vision Science from Santen for about $13 million in cash. Advanced Vision Science has made intraocular lenses since 1975 and supplies Santen’s Eternity lens in Japan. It also licenses glistening-free hydrophobic acrylic material to Bausch + Lomb for the enVista line. Those supply and license arrangements stay in place. SpyGlass, which is developing a drug-pad lens implanted during cataract surgery for glaucoma, is buying the plant to secure commercial lens supply. (Link)
  8. Shionogi has agreed to acquire Austin-based IntraBio for $2.0 billion, adding the rare-disease therapy AQNEURSA. Shionogi is buying all outstanding shares of IntraBio, an Austin company founded in 2015, for $2.0 billion in upfront cash. IntraBio sells AQNEURSA, approved in the United States and Europe for neurological symptoms of Niemann-Pick disease type C and, as of September 18, for ataxia in ataxia-telangiectasia in the United States. The company becomes a subsidiary of Shionogi’s New Jersey unit. Closing is scheduled for November or December, subject to antitrust review. Shionogi bought the RADICAVA ALS franchise in April. (Link)
  9. AstraZeneca has agreed to invest $2 billion in newly issued equity of Summit Therapeutics (NASD: SMMT), taking about a 12 percent stake. AstraZeneca is buying convertible preferred equal to about 12 percent of Summit’s common stock, or 10.6 percent fully diluted. The stake sits alongside a clinical collaboration testing AstraZeneca’s Claudin-18.2 antibody-drug conjugate, sonesitatug vedotin, with Summit’s PD-1/VEGF bispecific ivonescimab in gastrointestinal cancers. Each company keeps rights to its own drug. The investment was announced September 29 and was expected to close within about a week. (Link)
  10. GE HealthCare (NASD: GEHC) has agreed to acquire SOFIE Biosciences from Trilantic North America for $945 million in cash. SOFIE is a U.S. contract manufacturer for PET radiopharmaceuticals, with 15 sites, 21 cyclotrons and a theranostics development site, plus U.S. rights to FAPI-74, a Phase III PET tracer aimed at pan-cancer imaging. The business will sit in GE HealthCare’s pharmaceutical diagnostics segment and gives the buyer a last-mile network for short-lived tracers. Closing is aimed at the first half of 2027, subject to regulatory approval. (Link)
  11. Lantern Pharma (NASD: LTRN) has agreed to sell 3,669,725 shares at $1.09 in a registered direct offering raising approximately $4 million, with up to $4 million more available from concurrent private placement warrants. Lantern Pharma (LTRN), a clinical-stage AI-native precision oncology company, entered a definitive agreement for a registered direct offering of 3,669,725 shares, or pre-funded warrants in lieu, priced at $1.09 each. Aggregate gross proceeds are expected to be about $4 million. In a concurrent private placement, investors receive unregistered warrants over an equal number of shares at a $1.09 exercise price, exercisable only after stockholder approval and expiring five years later; full cash exercise would add roughly $4 million. Closing was expected on or about September 30, 2026, with proceeds earmarked for working capital and general corporate purposes. (Link)
  12. Leica Biosystems, a Danaher (NYSE: DHR) company, has completed its acquisition of pre-analytical consumables maker StatLab Medical Products from private equity owners Linden Capital Partners and Audax Private Equity. Danaher (DHR) subsidiary Leica Biosystems completed its purchase of privately held StatLab Medical Products on September 28, 2026, acquiring the business from Linden Capital Partners and Audax Private Equity. Terms were not disclosed. The deal extends Leica’s end-to-end anatomic pathology portfolio across specimen collection and preparation, advanced staining, digital imaging and AI-enabled diagnosis. Management positioned the combination as a response to laboratories facing rising case volumes, increasing complexity and staffing pressure, and as support for Leica’s biopharma partnerships within Danaher’s connected diagnostics ecosystem. (Link)
  13. Goldman Sachs (NYSE: GS) and Charlesbank Capital Partners-backed MyEyeDr. has agreed to acquire the 300-plus office optometry division of Partners Group (SWX: PGHN)-owned EyeCare Partners for an undisclosed sum. MyEyeDr., backed by Goldman Sachs (GS) and Charlesbank Capital Partners, is buying EyeCare Partners’ optometry division, which spans more than 300 offices under the Clarkson Eyecare, EyeCare Associates, EyeCare Center, Nationwide Vision and The Eye Doctors brands. Partners Group (PGHN) acquired EyeCare Partners in a $2.2 billion deal in late 2019, while Goldman Sachs bought MyEyeDr. for $2.7 billion the same year; MyEyeDr. already runs roughly 1,000 locations across about 30 states. EyeCare Partners will apply proceeds to reduce debt and strengthen liquidity while focusing on ophthalmology and ambulatory surgical centers. Closing is expected in Q4 2026. (Link 1) (Link 2)
  14. APM Group has agreed to acquire occupational health provider Medcor, combining it with previously acquired WorkCare and its Assure employee assistance business into a 2,000-employee North American platform. APM Group announced on September 28 that it entered an agreement to acquire Medcor, subject to Federal Trade Commission approval, with financial terms and completion date undisclosed. The deal follows APM’s April acquisition of WorkCare. Combined with Assure, the three businesses would employ more than 2,000 people across 450 sites, with services in every U.S. state and territory and every Canadian province. The combined portfolio spans injury prevention, onsite medical services, occupational health screenings, injury triage, telehealth, case management, return-to-work support and mental health services. Medcor, founded in 1984, adds mobile occupational health and 24/7 telehealth. (Link)
  15. Flexpoint Ford has sold behavioral health pharmacy platform ArtesRx — a business it co-founded in 2023 with Dom Meffe — to healthcare specialist Linden Capital Partners. Flexpoint Ford announced the sale of ArtesRx to Linden Capital Partners for undisclosed terms, a sponsor-to-sponsor exit of a platform Flexpoint built from scratch just three years ago. ArtesRx, established in 2023 by Flexpoint and Dom Meffe, is a behavioral health pharmacy platform serving individuals who depend on complex medication regimens. Chicago-based Flexpoint, founded in 2005, writes $50 million to $500 million per transaction across minority and majority structures in both private and public companies. Linden, also Chicago-based and founded in 2004, invests exclusively in healthcare across services, products and distribution and prefers larger cheques. (Link)
  16. Charlesbank Capital Partners and Warburg Pincus-backed MB2 Dental has partnered with Honolulu-based Hawaii Pacific Dental Group in its 14th acquisition of 2026. MB2 Dental, the Dallas dental support organization backed by middle-market private equity firm Charlesbank Capital Partners and growth equity investor Warburg Pincus, formed a strategic partnership with Hawaii Pacific Dental Group. The Honolulu practice, led by Dr. Rohinton J. Patel, provides cosmetic, restorative, preventative and family dentistry. MB2 supports a nationwide network of more than 1,900 affiliated physicians and practice partners across general dentistry, orthodontics, cosmetic care and oral surgery. The transaction expands MB2’s footprint across Hawaii and the broader Pacific region and marks its 14th acquisition of 2026. Financial terms of the private transaction were not disclosed. Link (Link)
  17. Standard Dental Labs (OTCQB: TUTH) has acquired substantially all operating assets of Dr. Tooth, LLC — also known as Sheen Dental Laboratory and Hansen Incarnati — in a cash-and-stock asset purchase with earnout conditions. Standard Dental Labs (TUTH) closed the acquisition effective October 2, 2026, structured as an asset purchase combining cash and SDL common stock with performance conditions tied to retained customer revenue. Management estimates the acquired business adds just over $800,000 in annualized revenue, taking SDL’s estimated annualized base above $1.6 million and nearly doubling the prior estimate. SDL plans to move production to its Sarasota facility, reshoring work currently outsourced to China to lift utilization and facility profitability. Management believes the business can be rebuilt to more than $1.1 million in annualized revenue. (Link)
  18. Banner Capital, with healthcare private equity firm Seventeen Capital as strategic co-investor, has agreed to acquire Seaway Plastics Engineering, MME Group and Wright Engineered Plastics, forming medical device manufacturing platform Seaway Group under Executive Chairman Ron Labrum. Salt Lake City-based Banner Capital formed Seaway Group and entered a definitive agreement to acquire the three medical device contract manufacturers, with closing expected in the fourth quarter of 2026. Seventeen Capital, a healthcare private equity firm led by medical device executive Ron Labrum, is a strategic co-investor, and Labrum becomes Executive Chairman at close. Seaway Group is the third platform in Banner Capital Fund II, after Western Pavement Services and Roof Restoration Group. Banner targets founder-led Western U.S. businesses with $4 million to $15 million of EBITDA and managed $611 million as of June 30, 2026. (Link)
  19. Wandercraft has acquired Ekso Bionics from a subsidiary of ChronoScale Holdings (NASD: CHRN), uniting two medical exoskeleton pioneers into a global robotic mobility platform. Wandercraft acquired Ekso Bionics from a ChronoScale Holdings (CHRN) subsidiary in a transaction unanimously approved by both boards and signed and closed simultaneously; financial terms were not disclosed. The combination pairs Wandercraft’s advanced robotics, physical AI and EMEA leadership with Ekso’s U.S. presence, clinical evidence base and commercial reach. Atalante X and EksoNR support patients at more than 700 rehabilitation centers worldwide, with FDA clearances and CE marking covering stroke, spinal cord injury, multiple sclerosis and acquired brain injury, while Eve and Indego Personal address at-home mobility. Wandercraft will continue supporting all four products. (Link)
  20. The University of Kansas Health System has agreed to take full ownership of the St. Francis campus in Topeka from Ardent Health (NYSE: ARDT). The two have run St. Francis and affiliated Topeka sites as a joint venture since 2017, after the campus had been facing closure. Ardent has handled day-to-day operations. KU Health System has provided clinical and financial support. Ardent will stay involved for a period after closing. The transfer is expected by the end of 2026, subject to approvals. (Link)
  21. Biospring Partners has led a growth investment in CDMO Serán Bioscience alongside existing investors Vivo Capital and Bain Capital Life Sciences to fund a new commercial spray-drying facility in Bend, Oregon. Biospring Partners led the growth investment with continued participation from Vivo Capital, Bain Capital Life Sciences and Serán’s executive leadership. Proceeds support a greenfield commercial manufacturing facility on track for completion in Q3 2027, creating an integrated 200,000-plus square foot campus with OEB4 manufacturing, spray drying, nano-milling and finished-dose capabilities. Biospring, founded in 2020, is a healthcare growth buyout firm with more than $500 million under management focused on pharma services; Vivo manages roughly $5.8 billion. Serán employs over 200 people and plans up to 150 additional hires. (Link)
  22. Renovus Capital Partners portfolio company TJP has acquired life sciences market research firm Evolution Consulting & Research, completing an end-to-end research, strategy, creative, pull-through and analytics platform for pharma clients. TJP, a Conshohocken, Pennsylvania value and patient access agency owned by Renovus Capital Partners, acquired Evolution Consulting & Research. The add-on follows TJP’s earlier purchase of FX2 Virtual and gives clients continuity from upfront market research through strategy, creative, virtual field execution and analytics. CEO Rino Mariconda, also an operating partner at Renovus, said the deal fulfills the firm’s vision of a unified platform. Renovus, founded in 2010, invests in knowledge and talent industries including healthcare and life sciences services, and builds platforms through operational improvement and add-on acquisitions. Terms were undisclosed. (Link)
  23. Resonant Clinical Solutions has acquired Hamburg-based labfish rental solutions GmbH and its U.S. and U.K. affiliates, expanding its Equipment & Ancillaries business across Europe. Resonant Clinical Solutions, a Leesburg, Virginia clinical supply chain and sample lifecycle partner, acquired Labfish together with its U.S. and U.K. affiliates for undisclosed terms. Labfish rents scales, freezers, refrigerators, infusion pumps and monitors, supplies kitting and ancillaries, and operates one of the largest in-house calibration facilities serving clinical trials in Europe. It also provides Importer and Exporter of Record services and direct-to-patient logistics, working with partner depots in Argentina, Israel, Turkey and China to supply sites in more than 70 countries. Resonant has over 850 employees and has supported more than 2,500 clinical trials. (Link)
  24. Sheridan Capital Partners has acquired Durham, North Carolina-based single-use bioprocessing components supplier Carolina Components Group, its fourth platform acquisition of 2026. Chicago healthcare private equity firm Sheridan Capital Partners acquired Carolina Components Group, a 2020-founded supplier of ultra-pure components, custom-engineered single-use assemblies and process solutions serving more than 250 biopharmaceutical and contract manufacturing customers. CCG operates over 100,000 square feet of ISO Class 7 and Class 8 cleanroom and manufacturing space, scale Sheridan says regional competitors lack. Sheridan cited CCG’s supplier-agnostic model and its status as a founder-owned business at a growth inflection point. The deal is Sheridan’s fourth of 2026 after ICANotes, Tres Health and PtEverywhere. (Link)
  25. Chicago Pacific Founders has exited veterinary AI company CoVetAI following its acquisition by IDEXX Laboratories (NASD: IDXX), the first realization from CPF’s Pet Fund – Off Leash Capital. IDEXX Laboratories (IDXX) acquired CoVetAI, developer of an AI-powered clinical scribe and workflow platform for veterinary medicine, handing Chicago Pacific Founders the first realization from its specialist animal health fund. Financial terms were not disclosed. CPF was CoVet’s sole institutional investor and backed the company from an early stage; Pet Fund partner Gina Del Vecchio described IDEXX as the ideal owner to scale the product globally. The fund closed on September 16, 2026, holds six portfolio investments, and targets a companion animal market currently worth $288.4 billion and projected to reach $560.7 billion by 2034. (Link)
  26. Brady (NYSE: BRC) has sold its French first-aid business Securimed to Safe Life for about $59 million. Securimed, based in Cappelle-la-Grande, sells customized first-aid kits, protective equipment and emergency-response products, mostly to corporate health and safety departments in France. Brady bought the business in 2010. The price is about €53 million. Brady is an identification and safety-products company based in Milwaukee and is treating the unit as outside that core. (Link)

Venture Deals and Other

  1. Anthropic, PBC has confidentially submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission for a proposed initial public offering of its common stock, with share count and price not yet set. Anthropic, PBC confidentially submitted a draft Form S-1 to the SEC for a proposed initial public offering of its common stock. The submission gives the AI developer the option to go public once the SEC completes its review, with any offering dependent on market conditions and other factors. The number of shares to be offered and the price have not yet been set. The announcement was published under Rule 135 of the Securities Act of 1933 and is not an offer to sell or a solicitation of an offer to buy securities. No valuation, timetable, exchange or selling shareholders were disclosed. (Link 1) (Link 2)
  2. Lux Capital and Natural Capital have co-led a $251 million Series D in El Segundo-based in-orbit pharmaceutical processing company Varda Space Industries, joined by Founders Fund, Khosla Ventures, Caffeinated Capital, General Catalyst, 8090 Industries, Giant Step and Also Capital, at a $1.6 billion valuation. Lux Capital and Natural Capital led Varda Space Industries’ $251 million Series D, with Founders Fund, Khosla Ventures, Caffeinated Capital, General Catalyst, 8090 Industries, Giant Step and Also Capital participating. The round values the microgravity-enabled life sciences company at $1.6 billion and lifts total capital raised to $598 million. Varda has completed six reentry missions since 2023, with more than a dozen launches and reentries planned through 2028. Proceeds will increase flight cadence and deepen pharmaceutical partnerships toward the first medicine manufactured in space. (Link)
  3. B Capital has led a $33 million Series B in Austin-based microbiome testing company Tiny Health, joined by Spero Ventures, The Venture City, Overwater Ventures, Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels and Pari Passu Ventures. B Capital led Tiny Health’s oversubscribed $33 million Series B, bringing total funding to $46 million. Existing backers Spero Ventures, The Venture City and Overwater Ventures participated alongside new investors Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels and Pari Passu Ventures. B Capital manages more than $12 billion and takes a board seat through Senior Principal Nick Whitehead. Proceeds fund clinical research, practitioner education, the Powered by Tiny B2B platform and TinyAI, trained on nearly 200,000 microbiome profiles. Tiny Health also committed $5 million to a Microbiome Research Program. (Link)
  4. Canvas Ventures has led an oversubscribed $10 million Series A in San Francisco-based healthcare AI company Parakeet Health, with Blank Space Ventures, StoryHouse Ventures and HMC INQ participating. Canvas Ventures led Parakeet Health’s oversubscribed $10 million Series A, taking total funding to $13 million. The raise follows 10x annual recurring revenue growth over the past year. Parakeet’s platform manages inbound calls, proactive outreach, fax processing and web scheduling, and now serves six of the ten largest U.S. dermatology groups, supporting more than 2,800 providers across 1,100-plus locations. Canvas co-founder Rebecca Lynn cited the team’s ability to win major healthcare customers and deliver measurable ROI. Parakeet charges on a performance basis tied to verified results. Link (Link)
  5. Biotia has raised an oversubscribed $9 million financing from Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital, Red Bear Angels and Red Bear Ventures, alongside VillageMD co-founders Tim Barry and Clive Fields. New York clinical metagenomics company Biotia closed an oversubscribed $9 million round that exceeds its previously announced Series A. Investors include Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital, Red Bear Angels and Red Bear Ventures, plus VillageMD co-founders Tim Barry and Clive Fields. DigitalDx Ventures CEO Michele Colucci becomes board chair and Barry joins the board. Capital will scale Biotia’s New York laboratory, launch further women’s health diagnostics and expand into orthopedics. Its BIOTIA-ID urine test reports 97% sensitivity and 99% specificity. (Link)
  6. Cobalt Capital has led an undisclosed Series A in Los Angeles-based predictive movement health company p°Motion, joined by WME Group, Nimble Ventures, Canaan Ventures and Soul Ventures. Cobalt Capital led the Series A financing, building on support from a broader investor group including WME Group, Nimble Ventures, Canaan Ventures, Soul Ventures and strategic investors connected to professional sports, technology and institutional capital. Neither round size nor valuation was disclosed. Founded in 2019, p°Motion applies machine learning to an assessment methodology built on more than 40 years of movement research, and says it can identify certain injury risks up to 18 months before they occur — a company-reported claim without published validation data. Proceeds fund AI and engineering hiring plus commercial expansion into healthcare. (Link)
  7. Advent has led, and Temasek co-led, a $555 million Series G in Medicare Advantage insurer Devoted Health as part of a $1.18 billion financing. Devoted Health closed $555 million of Series G primary funding within a $1.18 billion primary and secondary financing. Advent led with Temasek as co-lead, joined by The Space Between — both independently and alongside Centricus — plus GIC, Franklin Templeton, Generation, VZVC, Emerson Collective, Premji Invest and Andreessen Horowitz. The same investors committed $622 million for a shareholder tender offer expected to close later in the fourth quarter. Membership has grown from 212,000 in December 2025 to 538,000 by September 2026, and Devoted is entering 342 new counties and five new states. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update September 28th, 2026

LECO_Weekly-Healthcare-News_9-28-2026Download

Healthcare Weekly News and Deals – Sept 28th, 2026

  1. Webster Equity Partners to acquire Lifecore Biomedical (NASD: LFCR) for $6.28 per share in cash plus CVRs, valuing the sterile-injectable CDMO at up to $663.7 million. Lifecore is a Chaska, Minnesota contract manufacturer for sterile injectables — syringes, vials and cartridges, including complex formulations — and a large producer of injectable-grade hyaluronic acid. Common holders get $6.28 a share in cash, a 49.5 percent premium to the September 25 close. Contingent value rights tied to 2028 and 2029 revenue and 2030 EBITDA can add $160 million in the aggregate, or $9.67 a share if every milestone hits. MidCap Financial, MSD Partners and Alcon committed the debt; Webster committed the equity. The merger agreement includes a 30-day go-shop. The company stays in Chaska under the Lifecore name, with a close aimed at year-end. (Link)
  2. Ardan Equity is investing in clinical trial technology company Clinical ink alongside existing backer GI Partners at a total enterprise value of more than $500 million. Healthcare software specialist Ardan Equity is investing in Clinical ink, the clinical trial technology company, alongside existing backer GI Partners. GI Partners acquired a majority interest in Clinical ink in August 2020, when prior investor NovaQuest stayed on as a minority holder and management invested significantly. The new round adds a sponsor that invests exclusively in healthcare software, while GI Partners keeps its exposure as Clinical ink builds on a platform that brings data, technology and patient science together for trial sponsors. (Link)
  3. Clearlake Capital Group and Charlesbank Capital Partners have agreed to inject approximately $175 million of preferred equity into distressed healthcare software provider Symplr, as part of a creditor-backed recapitalization designed to shore up its finances and extend its debt maturities. Clearlake Capital Group and Charlesbank Capital Partners will provide around $175 million of preferred equity to Symplr under a restructuring agreed with several creditor groups, with the sponsors deferring interest on newly issued junior debt to preserve cash. Second-lien lenders are expected to add $103.5 million through a first-out second-lien loan, while first-lien holders would receive a 100-basis-point coupon increase for extending the 2027 maturity by three years. Symplr’s roughly $1.2 billion first-lien term loan was recently quoted near 71.4 cents on the dollar amid concerns over AI’s impact on software. Company is held in a single-asset continuation vehicle. (Link)
  4. Existing shareholders Star One Global Capital Limited and Eliyahou Harari have fully funded an $18 million registered direct offering in Nasdaq-listed capsule endoscopy developer CapsoVision (CV), buying 3,163,444 shares at $5.69 each. CapsoVision (CV) has raised about $18 million through a registered direct offering funded entirely by existing shareholders Star One Global Capital Limited and Eliyahou Harari. Under a September 17 securities purchase agreement, the investors agreed to buy 3,163,444 shares at $5.69, a roughly 5% discount to the prior Nasdaq close, with no underwriter involved. The insider-backed raise, approved by the board and reviewed by the audit committee, strengthens the balance sheet of the Saratoga, California-based capsule endoscopy developer, which has a market value of about $299.8 million. Proceeds will fund sales and marketing, R&D and working capital as it advances AI-assisted CapsoCam Plus and a second-generation colon capsule. (Link)
  5. Lexeo Therapeutics (NASD: LXEO) has agreed to acquire Mantle Therapeutics for $8.3 million in cash and equity plus up to $13 million in milestones, adding Friedreich ataxia programs. Mantle is a private clinical-stage company with four Friedreich ataxia candidates designed to raise or replace frataxin in the brain. One is an oral combination already in patients; another is an RNA construct linked to an anti-TfR1 antibody fragment. On the same day Lexeo signed a sponsored-research agreement with Weill Cornell on intra-cisternal dosing of LX2006 and took options from Vivet Therapeutics and Apertura Gene Therapy. Management says the cash on hand still lasts into 2028. The acquisition is expected to close this quarter. (Link)
  6. Avesi Partners has made an investment in St. Louis-based New Age Medical, a spinal MedTech hub connecting manufacturers, sales reps, hospitals and surgeons. Avesi invests in lower-middle-market healthcare services and technology and now has more than $2.2 billion under management. New Age sits between implant makers and the operating room: more than 85 OEMs, 100-plus independent reps, 200-plus hospitals and surgery centers, and 350-plus spine surgeons. Founder and chief executive Kevin Bly remains in place with the current management team. The check is meant to move product from the plant to the table faster, not to recapitalize a clinic chain. (Link)
  7. GoodVets has acquired WellHaven Pet Health, adding more than 40 veterinary hospitals and taking the combined network from 75 to 116 locations. GoodVets, based in Chicago, has mostly opened hospitals from scratch with local veterinarians. WellHaven already runs more than 40 clinics across seven states, with clusters in the Pacific Northwest and the Midwest. Those sites will move onto GoodVets’ central operating model and, over time, onto the GoodVets name. Existing clinic teams and patient panels stay in place. Terms were not published. (Link)
  8. Prisma Health has agreed to acquire 36 South Carolina urgent care centers, formerly Doctor’s Care, from Novant Health. Novant had been running the former Doctor’s Care sites. Closing is set for November 1, when the clinics convert to the Prisma Health Urgent Care name and about 500 employees come across. Patients keep walk-in, booked and virtual visits — including respiratory tests, X-ray and labs — and gain a referral path into Prisma’s hospitals and specialists. Most locations stay put; a few may fold into a neighboring center, with affected staff offered jobs nearby. Purchase price was not disclosed. (Link)
  9. Forge, the B2B events and media company backed by Apollo Funds (APO), has agreed to acquire Becker’s Healthcare from Pamlico Capital, combining it with Fierce Healthcare and Life Sciences to create a scaled healthcare and life sciences media and events platform. Forge, formed by combining Emerald and Questex after their acquisition by Apollo Funds (APO) in July 2026, has signed a definitive agreement to acquire Chicago-based Becker’s Healthcare from Pamlico Capital. The deal includes Becker’s 16 annual conferences, more than a dozen digital publications and its newsletters, podcasts and executive communities, which reach over 1.5 million healthcare leaders. Combined with Forge’s Fierce Healthcare and Life Sciences, the platform will run more than 35 live events. (Link)
  10. May River Capital has sold Addison, Illinois-based environmental monitoring platform Dickson to Copeland, a portfolio company of Blackstone (BX), expanding Copeland’s cold chain monitoring capabilities for healthcare and life sciences customers. May River Capital has sold Dickson to Copeland, a Blackstone (BX) portfolio company with approximately 18,000 employees across more than 40 countries. May River acquired Dickson in April 2018 and turned the family-owned, single-site business into a global environmental monitoring platform serving customers in more than 50 countries from Illinois, France and Malaysia. During its ownership, May River invested in next-generation sensing and cloud-based monitoring and took private Oceasoft, a publicly traded French monitoring company. Dickson serves regulated life sciences, pharmaceutical, healthcare and medical device customers, advancing Copeland’s cold chain intelligence offering (Link)
  11. Arcventis Health Partners has made a majority growth investment in Chicago-based functional medicine and hormone health provider Aligned Modern Health, with existing investor Harbour Point Capital remaining a meaningful shareholder, to fund national telehealth expansion and the launch of peptide therapy. Arcventis Health Partners, a US healthcare investor with growth equity and growth buyout strategies, has taken a majority stake in Aligned Modern Health, while Harbour Point Capital stays on as a meaningful investor. AMH operates 15 clinics across Chicago, a telehealth practice serving patients in more than 20 states and a team of 100-plus clinicians spanning functional medicine, hormone replacement therapy, chiropractic care and acupuncture. The capital will fund national expansion, broader clinical offerings including newly launched peptide therapy, the digital patient experience and provider hiring. AMH accepts most major insurance, which sets it apart from self-pay and concierge models. No valuation was disclosed. (Link)
  12. 1315 Capital has led a growth capital investment in Richmond, Texas-based medical device developer and manufacturer Velentium Medical, joining existing investor Great Point Partners as a significant shareholder to scale commercial manufacturing of wearable and implantable devices. Philadelphia-based 1315 Capital, which manages over $1 billion, led a growth capital investment in Velentium Medical, a developer and manufacturer of active Class II wearable and Class III implantable medical devices. Great Point Partners, which manages about $1.7 billion, remains a significant shareholder. Velentium operates from a 50,000-square-foot manufacturing facility after expanding from an engineering shop into commercial production. Proceeds go to manufacturing capacity, product development and regulatory infrastructure. 1315 takes minority and majority stakes in commercial-stage healthcare and outsourced medtech companies. (Link)
  13. Newly launched Boston private equity firm Haelan Capital Partners has made its first investment in Boca Raton, Florida-based virtual acute care provider NuView Health, pairing its capital with an in-house team of experienced healthcare operators. Boston-based Haelan Capital Partners launched with an investment in NuView Health, a hybrid onsite and virtual care partner to hospitals and provider groups across ICU, neurology, stroke and infectious disease. Founded by Gregg Osenkowski and Scott Castle, Haelan pursues control buyouts of founder-owned, lower middle market tech-enabled healthcare services businesses. Its Growth Enablement Model places an in-house C-suite of healthcare operators alongside the investment team to build portfolio infrastructure. NuView has about 150 active providers across more than 60 facilities and a 15-year clinical track record, and its doctors have treated over one million US patients. No deal value was announced. (Link) (Link)
  14. 5th Century Partners has completed a strategic investment in ION PT Network, a founder-led physical therapy management company serving the workers’ compensation market, to refine its commercial strategy while preserving its clinician-led model. Chicago-based 5th Century Partners, which invests in lower middle-market healthcare and business services companies, has made a strategic investment in ION PT Network. Founded in 2017 by physical therapist Joseph Noel, ION manages workers’ compensation physical therapy for payers, employers and third-party administrators through independent providers, assigning each referral to a licensed clinical case owner; more than half its staff are licensed therapists. 5CP plans to refine ION’s business and commercial strategy while preserving its clinical model. Noel remains CEO, supported by newly added chief revenue officer Sara Mulick and chief financial officer Alina Schreiber. Terms were not disclosed. (Link)
  15. Ascend Learning has acquired AI-powered healthcare workforce scheduling platform M7 Health, combining it with its StaffGarden and Laudio brands to support clinicians from schooling through day-to-day staffing. Boston-based Ascend Learning, a healthcare and learning technology company, has acquired M7 Health, whose AI platform forecasts staffing demand, balances schedules and recruits to fill gaps for health systems ranging from academic medical centers to rural hospitals. M7 customers have cut administrative burden by more than 60%, premium labor spend by 35% and nurse turnover by 30%. The deal pairs M7 with Ascend’s StaffGarden and Laudio brands, extending a platform that supports more than 60% of nursing schools and 245,000 allied health professionals a year. It follows Ascend’s August acquisition of TAMS, continuing its expansion in healthcare workforce technology. Terms were not disclosed. (Link)
  16. Carisk Partners has acquired onsite occupational healthcare provider FirstCare Onsite to connect injured workers with care from the point of injury through complex recovery in the workers’ compensation market. Tampa-based Carisk Partners, a specialty risk transfer, care coordination and clinical services company in workers’ compensation, has acquired FirstCare Onsite. FirstCare places clinicians at employer worksites and has historically resolved roughly 30% of workplace injuries before they became claims. Carisk will keep FirstCare’s onsite model while routing complex cases into its specialty care, complex care management and behavioral health services. Carisk plans to invest in expanding FirstCare’s onsite programs, particularly among large employers with concentrated workforces. (Link)
  17. MGA Homecare has acquired Care IV Home Health’s private duty nursing division, entering Arkansas as its seventh state and expanding in-home care for medically complex pediatric and adult patients. MGA Homecare has acquired Care IV Home Health’s private duty nursing division, which has served medically complex Arkansas patients for more than three decades, including children and adults who depend on ventilators or tracheostomies. The carve-out let’s Care IV focus exclusively on its Medicare intermittent skilled home health business. MGA is keeping the division’s leadership, headed by Joseph Kennon, and its nursing workforce, and plans to use the unit to reach rural and underserved patients and pursue value-based partnerships with health plans. MGA now has more than 5,500 team members serving over 6,000 patients daily across seven states. Terms were not disclosed. (Link)
  18. Nashville-based Chord Specialty Dental Partners has entered Ohio by partnering with Ohio-based pediatric practices Prairie Kids Dental of West Jefferson and Clover Kids Dental of Columbus, extending its network to eight states. Chord Specialty Dental Partners, a Nashville-based dental support organization, has partnered with two Ohio pediatric practices: Prairie Kids Dental in West Jefferson and Clover Kids Dental in Columbus. Both practices are led by founder Kimberly Gill, DDS. The deal marks Chord’s entry into Ohio and brings its footprint to eight states. Chord supports more than 60 partner practices across pediatric dentistry, orthodontics, oral surgery and ambulatory surgery centers. The deal adds to an active consolidation market: professional services, the segment Healthcare DealHub files it under, leads that site’s 2026 year-to-date healthcare deal count with 386 transactions. Terms were not disclosed. (Link)
  19. Hope Network has acquired Developmental Enhancement Behavioral Health, a roughly 90-person West Michigan autism services provider, nearly doubling the footprint of its Center for Autism. Michigan’s Hope Network has acquired Developmental Enhancement Behavioral Health, a roughly 90-person provider of Applied Behavior Analysis, psychological assessment and counseling with locations in Grand Rapids, Holland and Georgetown Township. The deal nearly doubles the footprint of Hope Network’s Center for Autism, which operates in Kentwood, Holland Township, Livonia and Okemos. Financial terms were not released. Integration is planned in phases through about spring 2027. DE locations, clinicians and care models stay in place, with no immediate rebranding. (Link)
  20. Penn Medicine, Independence Blue Cross (IBX) and Regent Surgical have formed a new joint company to develop at least 18 ambulatory surgery centers across Greater Philadelphia, combining health-system, payer and ASC operator capabilities to shift procedures into lower-cost outpatient settings. Penn Medicine, Independence Blue Cross and Regent Surgical are launching a new company to develop at least 18 ambulatory surgery centers across Pennsylvania, New Jersey and Delaware. Penn brings the clinical network, IBX the payer, and Regent the ASC development and operating platform. Hospital facility fees can run close to twice ASC fees; Vizient has projected outpatient surgical volumes up 20 percent through 2035. No financial terms were disclosed. (Link)
  21. OceanSound Partners-backed PAR Excellence Systems, based in Cincinnati, Ohio, has acquired Madison, Wisconsin-based healthcare RFID inventory tracking company Terso Solutions from Promega Corporation to build a unified hospital inventory management platform. PAR Excellence Systems, an OceanSound Partners portfolio company, has acquired Terso Solutions from its parent, Promega Corporation. Terso makes ultra-high-frequency RFID enclosures, open-air readers and cloud software that let hospitals track high-value inventory in real time, with thousands of enclosures installed across hundreds of hospitals and health systems, including the US Department of Veterans Affairs. The companies have worked together for years, and hundreds of PAR clients already connect Terso enclosures to PAR’s TrackCore tissue and implant tracking software. The combined business serves about 1,700 hospitals, nearly 30% of the roughly 6,000 in the US, and aims to replace fragmented point solutions. Financial terms were not disclosed. (Link)
  22. RS2 Healthcare Partners has completed its first new platform investment since refocusing exclusively on healthcare, backing Hatboro, Pennsylvania-based medical device contract manufacturer KMM Group and appointing J. Mark King as CEO. Boston-based RS2 Healthcare Partners, formerly Riverside Partners, has invested in KMM Group, a vertically integrated precision contract manufacturer of complex, tight-tolerance components for the medical device industry. The deal is RS2’s first new platform since the firm rebranded earlier this year to focus exclusively on lower middle-market healthcare; RS2 has raised $1.6 billion in total commitments since its 1989 founding. RS2 appointed J. Mark King, previously CEO of former RS2 portfolio company Tegra Medical, as KMM’s president and CEO. Founders John Shegda and Eric Wilhelm stay on as chief technology officer and executive vice president of business transformation, respectively. No terms were announced. (Link)
  23. Arlington Capital Partners portfolio company AVS Bio has acquired Cambridge, UK-based bio-reagent supplier Biorbyt Ltd. to expand its biomaterials catalog and ecommerce capabilities. AVS Bio, a Norwich, Connecticut provider of bioprocessing inputs and services backed by Arlington Capital Partners, has acquired Biorbyt Ltd., a Cambridge, UK supplier with more than 1 million SKUs of antibodies, proteins, ELISA kits and molecular biology reagents. The add-on expands AVS Bio’s research catalog and adds Biorbyt’s ecommerce channel. Arlington is investing from its $6 billion Fund VII. Biorbyt’s leadership team stays in place. (Link)
  24. Audax Private Equity-backed Elevate ENT Partners has acquired West Texas Ear, Nose & Throat, expanding its otolaryngology physician practice management platform across Texas. Elevate ENT Partners, backed by Audax Private Equity, has acquired West Texas Ear, Nose & Throat, which operates locations in Abilene and Brownwood. The practice is led by its sole physician, Dr. Jason Acevedo, with 11 healthcare and administrative staff, and provides otolaryngology, head and neck surgery and allergy treatment. The deal is Elevate’s first practice acquisition of 2026 and extends its reach across Texas. Elevate supports a national network of more than 80 otolaryngology centers and over 130 affiliated physicians. It gives physician-led ENT and allergy practices management infrastructure, revenue cycle management, payer contracting, human resources and operational scale. Financial terms were not disclosed. (Link)
  25. Rays of Belief Limited (MOMSBELIEF), operating as Mom’s Belief, has acquired 100% of New York-based pediatric Early Intervention provider City Pro Group through its subsidiary Mom’s Belief US Inc. to build a US developmental care platform. India-based Rays of Belief (MOMSBELIEF), which runs 136 developmental care centres under the Mom’s Belief brand, has acquired all of City Pro Group through wholly owned subsidiary Mom’s Belief US Inc., effective September 18, 2026. Founded in 1995, CPG provides pediatric Early Intervention and special education services across the Bronx, Brooklyn, Manhattan and Long Island. CPG generated US$11.43 million (about ₹97.27 crore) of FY25 revenue, more than the acquirer’s FY26 consolidated revenue of ₹81.66 crore, so the deal could roughly double the group’s scale. The acquisition gives the company a US operating platform and a two-way exchange of clinical know-how between India and the US. Consideration was not disclosed. (Link)

Venture Deals and Other

  1. Pershing Square Inc. (PS), the Ackman Oxman Institute and an undisclosed life sciences investment fund have co-led Precision Neuroscience’s oversubscribed $250 million Series D, joined by Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners (parent Korea Investment Holdings, KRX: 071050), Hitachi Ventures (parent Hitachi, TYO: 6501) and JSL Health Capital, to advance its brain-computer interface toward commercialization. Pershing Square Inc. (PS), the Ackman Oxman Institute and an undisclosed life sciences fund co-led Precision Neuroscience’s oversubscribed $250 million Series D, lifting total capital raised to $430 million since the brain-computer interface developer was founded in 2021. Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners (parent KRX: 071050), Hitachi Ventures (parent TYO: 6501) and JSL Health Capital also joined, spanning sovereign wealth, venture, public-market and family-office capital. Precision holds FDA clearance for its Layer 7 cortical interface, has completed more than 100 procedures across 18 institutions and partners with Medtronic (MDT). Proceeds will fund clinical expansion, further FDA review and commercialization. (Link)
  2. Francisco Partners has led a $155 million Series E in pharmacy benefit management and care navigation company Rightway, with participation from existing investors Thrive Capital and Khosla Ventures, to expand its AI and technology capabilities. Francisco Partners led a $155 million Series E in New York-based Rightway, with existing investors Thrive Capital and Khosla Ventures participating. Rightway provides pharmacy benefit management and care navigation for employers. Its financial model removes any incentive to profit from higher drug spend, and pharmacists guide members to the most appropriate medications at the lowest cost. It now counts 45 Fortune 500 companies as clients, nearly 10% of the index. Its SureSpend model caps total pharmacy spend and covers GLP-1s and rare high-cost drugs at net cost with 100% rebate pass-through. Proceeds will expand Rightway’s AI and technology. Francisco Partners, with over $75 billion raised, brings healthcare technology expertise. (Link)
  3. .406 Ventures has led a $22 million Series A in at-home cervical cancer screening company Teal Health, with continued backing from Emerson Collective (managed by Yosemite), Forerunner and Serena Ventures and new participation from Japan-based MPower Partners, ahead of broad insurance coverage in 2027. .406 Ventures led a $22 million Series A in Teal Health, maker of the Teal Wand, the first FDA-authorized self-collection device for at-home HPV cervical cancer screening. Emerson Collective (managed by Yosemite), Forerunner and Serena Ventures returned, and Japan-based MPower Partners joined, lifting total funding to $45 million. Federal guidelines due in January 2027 require most health plans to cover self-collection screening. Proceeds go to payor, health system, employer and provider contracts, direct-purchase channels and hiring. Teal reports that 59 percent of women who use the wand had been underscreened. (Link)
  4. NEA has led a $20 million Series A in Nashville-based AI post-acute admissions platform Basalt Health, with participation from existing investors Frist Cressey Ventures and 25m Health, to scale across Lifepoint Health and ScionHealth hospitals. Return investor NEA led a $20 million Series A in Nashville-based Basalt Health, with existing backers Frist Cressey Ventures and 25m Health, 25madison’s healthtech venture studio, participating; total funding now stands at about $24.5 million. Basalt’s AI reads post-acute referrals and checks them against clinical and payer rules, cutting median processing time by 86% at Lifepoint Health. The capital will support scaling across 111 markets by the end of 2026, including 62 ScionHealth hospitals and 49 Lifepoint markets, plus expansion into discharge and payer workflows. NEA, with more than $38 billion in assets under management, and Frist Cressey, with $846 million, bring deep healthcare networks. (Link)
  5. Accel has led a $10 million seed round in New York-based healthcare conversational AI company Clarion Health, with participation from Y Combinator, to automate scheduling, referrals, prescription refills and patient communications for providers. Accel led a $10 million seed round in New York-based Clarion Health, with participation from Y Combinator. Clarion’s conversational AI platform automates scheduling, referrals, prescription refills and patient communications for healthcare providers. Founded in 2024 by Ryan Gallagher and Jeffrey Lamothe, the company is building what Y Combinator calls an AI communication layer for healthcare, with agents that handle the overwhelming volume of calls and messages providers receive. The Accel-led round gives the two-year-old startup capital to scale its AI communication infrastructure for healthcare providers, and the company is actively hiring following the raise. (Link)
  6. Surgeon investors have backed Redefine Surgery’s oversubscribed pre-seed round, bringing total capital raised to $10 million, as Catalyst OrthoScience joins as Founding Partner to co-develop surgical intelligence for shoulder replacement. Redefine Surgery has closed an oversubscribed pre-seed round backed mostly by surgeon investors, bringing total capital raised to $10 million. The company is combining computer vision, software and robotics in a portable platform for the operating room, starting in orthopedics. Naples, Florida-based Catalyst OrthoScience joined as founding partner on surgical intelligence for shoulder replacement. More than 25 surgeons advise the company. Commercial use still requires regulatory clearance. (Link)
  7. Ground State Ventures has led a $3.4 million pre-seed round in Azulene Labs, with participation from existing investor Entrada Ventures and angel investors, to build physics-based AI models for drug and materials simulation. Ground State Ventures led a $3.4 million pre-seed round in Azulene Labs, with participation from existing investor Entrada Ventures and angel investors. Azulene builds physics-based models trained on quantum-mechanical data for drug and materials simulation. Co-founder Nicolas Sawaya previously led quantum chemistry algorithm work at Intel Labs. Proceeds go to hiring and to work with biotech and industrial chemistry customers. (Link)
  8. Elmstead Partners, Chisos Capital, the Chemical Angel Network and individual angel investors have backed Axio BioPharma’s $2.4 million pre-seed round to connect biomanufacturing data between pharma companies and their manufacturing partners. Elmstead Partners, Chisos Capital, the Chemical Angel Network and a group of individual angels invested in Axio BioPharma’s $2.4 million pre-seed round. The Madison, Wisconsin company connects manufacturing data between drug sponsors and their manufacturing partners through a product called Lattice, with each side keeping its own systems. Proceeds fund first deployments with design partners and further work on Rosetta, an ontology layer that maps those systems to each other. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update September 21st, 2026

LECO_Weekly-Healthcare-News_9-21-2026Download

Healthcare Weekly News and Deals –Sept 21st, 2026

  1. CareTrust REIT (NYSE: CTRE) Acquires Southwest Skilled-Nursing Portfolio for $400 Million First public print of a transaction effective September 1. The book is 2,622 licensed SNF beds, triple-net to the incumbent operator with inflation escalators and renewal options. Structured as a joint venture; CareTrust put in about $380 million from cash and settled equity forwards and models an 8.6% stabilized yield. Sourced off-market in markets where both landlord and operator already have scale. Year-to-date deployment is now about $1.9 billion and Q3-to-date about $710 million. Management reloaded the near-term pipeline at about $600 million. (Link)
  2. Lisata Therapeutics (NASD: LSTA) Acquires Marea Therapeutics; $225 Million PIPE Concurrent Stock-for-stock reverse merger plus PIPE. RA Capital, Forbion, Third Rock, Alpha Wave, Perceptive, Sofinnova, Omega, Surveyor/Citadel, Columbia Threadneedle, Nantahala, Affinity, venBio and Rock Springs filled the round. Combined cap table: legacy Lisata about 2.4%, Marea holders about 59.5%, PIPE about 38.1%. Assets are MAR001/005, an ANGPTL4 monoclonal in Phase 2b for severe hypertriglyceridemia, and MAR002, a growth-hormone-receptor antagonist headed to Phase 2 in acromegaly. Runway into 2028; key reads targeted for the fourth quarter of 2027. (Link)
  3. Veracyte (NASD: VCYT) acquires Convergent Genomics for $150 million in cash plus up to $30 million in milestone payments, adding urine-based bladder cancer testing. Veracyte closed its purchase of Convergent Genomics on September 14. It paid $150 million in cash at closing, subject to customary adjustments, with up to $30 million more tied to UroAmp publication and reimbursement milestones. Convergent was founded in 2015 in partnership with Oregon Health & Science University and runs a CLIA-certified lab in South San Francisco. Its UroAmp urinary tumor DNA assay is validated for monitoring therapy response and post-treatment surveillance in non-muscle-invasive bladder cancer. The asset sits alongside Decipher Bladder and TrueMRD, so Veracyte now covers urine, tissue and blood across the bladder cancer pathway. Management expects no material impact on 2026 EBITDA guidance. (Link)
  4. Oaktree commits up to $115 million in milestone-based capital to Saol Therapeutics ahead of the FDA decision date for SL1009. Funds managed by Oaktree will provide up to $115 million to Saol Therapeutics, a private clinical-stage drug company in Roswell, Georgia. An initial tranche funds launch preparation, and the rest is released as regulatory, clinical and commercial milestones are met. The lead drug, SL1009 (sodium dichloroacetate), treats pyruvate dehydrogenase complex deficiency, a rare mitochondrial disease with no approved therapy. The FDA rejected an earlier application in 2025. Saol resubmitted, and the FDA’s decision date is December 30, 2026. Later tranches would fund SL1009 in congenital lactic acidosis and expand SL1002 into more pain indications and spasticity. (Link)
  5. Agora makes a $47 million first investment in Vheda Health, a Columbia, Maryland outcomes and analytics platform for health plans. Agora is a San Francisco private equity firm focused on healthcare technology, founded by Neil Vangala. It has invested $47 million in Vheda Health. This is Agora’s first deal and the first institutional capital in Vheda’s 13-year history. The previously bootstrapped company runs chronic-condition and maternity programs for high-risk Medicaid, Medicare and Special Needs Plan members. It cites more than $975 million in savings for health plan partners and an average 3:1 return on investment. Co-founder and CEO Shameet Luhar stays. The money funds expansion beyond 18 states, new analytics products and targeted acquisitions. (Link)
  6. Ambu (Nasdaq Copenhagen: AMBU B) acquires U.S.-based TIMS Medical (Foresight Imaging) for $45 million upfront plus up to $20 million in milestones to advance its EndoIntelligence platform. Ambu, the Danish single-use endoscopy leader, has bought Foresight Imaging, LLC, which trades as TIMS Medical. It is paying $45 million upfront and up to $20 million in milestones, for total consideration of as much as $65 million. Founded in 2004, TIMS builds hardware and software that record procedure imaging and integrate it into hospital EMR and imaging systems. Its flagship TIMS MVP is widely used in ENT procedures, including FEES exams. The business has about 55 employees, roughly $15 million in annual revenue and around 7,000 installations across U.S. hospitals. Ambu expects the deal to accelerate revenue growth and kept its FY2025/26 outlook unchanged. (Link)
  7. WJRJJ Ventures, owned by Copart (NASD: CPRT) founder Willis Johnson, completes a $40 million private placement in HealthStream (NASD: HSTM). WJRJJ Ventures bought 1.5 million HealthStream shares at $29.50 each. That comprised 1,355,932 new shares for about $40 million and 144,068 existing shares bought from CEO Robert Frist Jr. for about $4.25 million. Frist remains the largest shareholder, with about 16.4%. Johnson, a Nashville-area entrepreneur, was also the first investor in Empath Nursing, founded in 2025. HealthStream sells workforce technology to hospitals and will use the money for product investment and possible acquisitions. (Link)
  8. Arsenal Capital Partners–backed Endpoint Clinical acquires Boston-based Bluefin, a clinical supply forecasting and planning technology provider. Endpoint Clinical, the randomization and trial supply management vendor Arsenal acquired in 2024, has bought Bluefin, a Boston cloud platform for planning clinical supply demand and distribution. The add-on moves Endpoint upstream from RTSM execution into forecasting. Supply plans will link to live enrollment and inventory data, so sponsors can anticipate shifts rather than react to them. Bluefin will keep operating independently and will still connect to competitors’ RTSM systems. Endpoint will add implementation, quality, project management and customer support. Bluefin CEO Andy Maltun stays. (Link)
  9. Seven Hills Capital–backed Spa Medicca of Canton, Ohio acquires Dr. Nicholas E. Sherock LLC & Associates, an Ohio women’s health practice in Massillon and Orrville. Spa Medicca has acquired Dr. Sherock & Associates, a two-location women’s health group in Massillon and Orrville. Dr. Nicholas Sherock leads a five-person clinical team offering gynecologic care, hormone replacement therapy, minimally invasive surgery and aesthetic services. Those services map onto Spa Medicca’s focus on medical aesthetics, hormone optimization and women’s health. The deal adds density in northeast Ohio after earlier work such as Amy Brenner, MD & Associates in Cincinnati. Patients keep existing providers and locations. (Link)
  10. Gauge Capital–backed Reliable Medical acquires Freedom in Mobility and Action Seating & Mobility, expanding CRT coverage across Alabama, Tennessee, Oklahoma, Arkansas and Colorado. Reliable Medical is a Nashville CRT and home medical equipment provider Gauge recapitalized from Seven Hills in January. Freedom in Mobility adds three sites in north Alabama and Tennessee; president Teresa Glass Owens and COO Forrest Owens join. Action Seating & Mobility adds Tulsa, Oklahoma City, Muskogee, Fayetteville, Sherwood and Denver — manual and power chairs, custom seating, ATP-led fitting and repair. Combined network is more than 50 locations. Two add-ons in one week on the same platform. (Link)
  11. NMS Capital launches Asurgence Medical by recapitalizing ENDOCORP and acquiring Medical Optics from Probo Medical. NMS partnered with management to recapitalize Endoscopy Corporation of America of Southfield, Michigan and at the same time bought Medical Optics of Tamarac, Florida from Probo Medical. ENDOCORP supplies more than 15,000 repair-part SKUs for flexible endoscopes. Medical Optics repairs and resells flexible and rigid scopes across manufacturers. Both keep their names as Asurgence subsidiaries. Former Probo CEO Michael Asmer becomes CEO. Thesis is aging equipment fleets and hospital pressure to avoid OEM overhaul pricing. (Link)
  12. Amulet Capital Partners closes a continuation vehicle to recapitalize US Fertility. New and existing investors participated. US Fertility was formed in 2020 and now supports more than 120 clinic and IVF lab locations and over 200 physicians. It has treated more than 400,000 patients. The deal builds on L Catterton’s 2025 entry as co-lead alongside Amulet and the physician partners. Amulet, a healthcare-only sponsor managing about $3.8 billion, stays involved. The new capital funds geographic expansion and clinical innovation. (Link)
  13. Sheridan Capital Partners acquires a majority stake in PtEverywhere, a Raleigh-based practice management and payments platform for physical therapy clinics. Sheridan completed a majority investment in PtEverywhere. The Raleigh platform brings scheduling, clinical documentation, billing and collections into one workflow for small and mid-sized outpatient physical therapy clinics, including cash-pay and hybrid reimbursement models. CEO Andrew Shofner stays. Sheridan plans organic growth and add-ons that broaden the product into adjacent rehab segments. The deal sits next to Sheridan’s 2025 investment in post-acute billing vendor National Care Systems. (Link)
  14. Martis Capital– and Din Ventures–backed Archway Dental Partners acquires Veale Dental, its first Massachusetts practice. Archway Dental Partners, based in Danbury, Connecticut, acquired Veale Dental, a two-location general practice in South Easton and Dartmouth. This is Archway’s first Massachusetts practice and its third acquisition of 2026, after five deals in 2025. The group began as the four-location Dental Associates of Connecticut and now supports more than 40 practices across Connecticut and New York. Entry into a new state rather than an add-on in an existing market. (Link)
  15. Neuberger and KKR (NYSE: KKR) agree to acquire a significant minority stake in Datavant, which remains controlled by New Mountain Capital. Funds managed by Neuberger Capital Solutions and Neuberger Private Markets, together with KKR’s Strategic Investments Group, agreed to buy a significant minority stake in Datavant. New Mountain Capital, an investor since 2014, keeps control. Datavant’s network spans more than 80,000 providers and 75 of the top 100 health systems, and its data touches about 90% of the U.S. population. Growth capital into a scaled asset rather than an exit, funding further digitization and clinical AI. Closing expected in the fourth quarter of 2026. (Link)
  16. Parthenon Capital–backed MRO acquires Vyne Medical from TJC-owned Vyne, adding clinical data intake and document processing. MRO, a Norristown clinical data management platform, acquired Vyne Medical from Vyne, a TJC portfolio company. Vyne Medical turns paper, fax, voice and image inputs into structured data for more than 800 hospitals. Together the companies serve over 2,500 hospitals and 35,000 clinics. Intake tools feed MRO’s medical-records release and data exchange services. Vyne Dental is not part of the deal and stays with TJC. Clean sponsor-to-sponsor handoff. (Link)
  17. NewSpring-, Kineticos-, HealthQuest- and Great Point–backed Kincell Bio Merges with Cellipont to Form Kincellis Advanced Therapies U.S. cell-therapy CDMO combination. Kincell’s immune-cell shop plus Cellipont’s stem, iPSC, MSC, dendritic, exosome and mRNA work. About 140,000 square feet across Gainesville, Research Triangle Park and The Woodlands; 16 qualified GMP suites; more than 150 GMP batches released; 10 INDs this year; 200-plus staff. Darren Head is CEO. Equity led by NewSpring with Kineticos Life Sciences, HealthQuest Capital and Great Point Partners; debt from J.P. Morgan. (Link)
  18. Arlington-Backed Everest Clinical Research Acquires Firma Clinical’s Data Services Unit Toronto data-first CRO buying Firma DS, a biometrics and clinical-data book that has touched more than 1,000 studies and 60-plus NDAs across oncology, neurology, rare disease, hepatology and nephrology. Adds delivery capacity in the U.S. and Asia-Pacific. Firma DS clients get Everest’s full-service stack — regulatory, operations, safety, medical writing — on one CRO. Arlington Capital has owned Everest since 2020. (Link)
  19. Gauge-Backed Rovia Clinical Research Acquires Pinnacle Research Group and Cullman Clinical Trials in Alabama Site-network add-ons on Gauge’s Rovia platform. Pinnacle is an Anniston-area multi-specialty site founded in 1998, with 500-plus completed trials and Phase I capability. Cullman Clinical Trials is its north-central Alabama partner site. The pair gives Rovia owned density in a state it did not previously control. Gauge has funded the site roll-up since the 2024 platform launch. Separate from Reliable Medical, another Gauge healthcare vehicle. (Link)
  20. HealthEdge- and United Western–Backed Veridian Healthcare Acquires ScarScience from Mitchell-Vance Medical-grade silicone scar sheets and gels into plastic surgery, dermatology and physical-therapy channels. Brand add-on onto a wound-and-scar distribution platform rather than a clinic buy. Robert Friedberg remains CEO; Jessica Rowen stays on the seller side of the handoff. HealthEdge Investment Partners and United Western Group are the sponsors. (Link)
  21. Medallion acquires Andros, an NCQA-certified credentials verification organization, creating a credentialing platform covering more than one million providers. Medallion, a San Francisco AI-assisted credentialing and payer-enrollment platform, acquired Andros, an NCQA-certified CVO serving health plans, health systems, provider groups and telehealth companies since 2013. The combination brings more than one million providers across nearly 400 organizations and health plans onto one platform. Andros verifies data on more than 8 million providers and runs about 300,000 credentialing checks a year. Health-plan customers will move onto Medallion’s automated verification tools and AI outreach agents. (Link)
  22. Abry Partners–backed Centauri Health Solutions of Tempe, Arizona acquires Iowa-based Benny the Benefits Navigator to expand its SSI/SSDI eligibility technology. Centauri acquired Benny the Benefits Navigator, an Iowa startup founded in 2024 by Jeremy Shapiro, James Vancel and Joel Segre. Its AI platform replaces paper forms with a conversational digital intake for SSI and SSDI applications. Benny folds into Centauri’s Member Connect disability eligibility service, which already reaches more than 60 million lives. Latest add-on under Abry after the 2025 MedAllies purchase. (Link)
  23. Ignitus Recovery acquires AIM Health Boulder, a Colorado mental health and substance-use treatment program for young adults. Englewood-based Ignitus acquired AIM Health Boulder, a 20-year Boulder program treating adults 18–30 through PHP and IOP at the historic Earl House. Ignitus plans to keep existing programs and add residential treatment, alumni engagement and long-term recovery support. Founder Danny Conroy said he chose Ignitus to carry the program forward. CEO Steve Millette committed to no disruption for clients, staff or referral partners. (Link)
  24. Stony Brook Medicine Community Medical Group acquires South Shore Digestive Medicine, a Bay Shore, New York gastroenterology practice led by Dr. Darius Sorbi. The community physician arm of Stony Brook Medicine acquired South Shore Digestive Medicine in Bay Shore. Dr. Darius Sorbi trained in internal medicine at Stony Brook and completed his GI fellowship at Mayo Clinic. He specializes in advanced endoscopy, biliary and pancreatic disease and GI cancers. The practice is now listed at 10 Brentwood Road, Bay Shore, alongside Stony Brook GI sites in Commack and Lake Grove. Extends the SUNY-owned academic system’s coverage onto Long Island’s South Shore. (Link)
  25. AKTIV Against Cancer Merges with CancerFit Exercise-oncology combination. AKTIV is the U.S. sister of Norway’s Aktiv mot kreft — hospital gyms branded Pusterom in Norway and AKTIVcenter in the U.S., research funding at Memorial Sloan Kettering, first U.S. site at Summit Health in New Jersey. CancerFit is the digital and program counterpart. No price and no cap table on the open wire. Merger of two mission-aligned exercise-as-treatment platforms, not a clinic roll-up. (Link)
  26. Daia Orthodontics & TMJ Orthopedics acquires four former docbraces clinics in New Brunswick and Prince Edward Island, its first expansion outside the U.S. Rochester Hills, Michigan-based Daia acquired four clinics that previously operated under the docbraces name, in Grand Falls and Woodstock, New Brunswick, and Charlottetown and Summerside, Prince Edward Island. The founder-owned practice goes from one location to five. Founder Dr. Hadi Daia is certified in both the U.S. and Canada and has treated patients at these clinics since 2021, converting an existing clinical relationship into ownership. Current clinical and administrative teams stay. No outside sponsor was named. (Link)
  27. Medartis Holding (SIX: MED) Acquires M.A.R.C. Institute in Doral, Florida First permanent training site outside Europe and the group’s largest, with 36 surgical stations and capacity for 140 participants. Name and general manager Heloise Peixoto stay; the IBRA partnership continues; universities, societies and other device companies keep access. Satellite activity in São Paulo, Rio and Curitiba. Osteosynthesis implant maker buying education infrastructure, not a clinic roll-up. (Link)
  28. Xenetic Biosciences (NASD: XBIO) to Acquire Santersus AG in an All-Stock Exchange; Combined Company to Be Santersus Bio Agreement dated September 14, public print September 16. Swiss NucleoCapture blood-purification device plus Xenetic’s DNase platform against neutrophil extracellular traps. Santersus holders about 85%, Xenetic about 15% on a fully diluted basis. Pipeline includes Breakthrough Device-designated work in sepsis and SLE. Combined company expected to trade as Santersus Bio. Close targeted in the fourth quarter on a stockholder vote and Nasdaq listing of new shares. (Link)

Venture Deals and Other

  1. Vitruvian Partners leads Angle Health’s $600 million financing at a $2.7 billion valuation, with Town Hall Ventures, Blumberg Capital, Portage Ventures, Prudential Financial (NYSE: PRU)’s PruVen Capital and Y Combinator participating. London-based Vitruvian Partners led a $600 million equity financing in Angle Health at a headline $2.7 billion valuation. It combines a $200 million Series C with a $400 million tender offer for existing shareholders. New investor Town Hall Ventures joined existing backers Blumberg Capital, Portage Ventures, PruVen Capital and Y Combinator. The San Francisco company provides AI-driven health benefits to more than 5,000 small and mid-sized employers, with nearly $1 billion in annualized premiums. It reports 120% growth and four profitable quarters in a row. (Link)
  2. Thoreau leads a $100 million funding commitment to Penelope Health, with Bertelsmann Healthcare Investments, Twine Ventures and Seedcamp participating. Thoreau, the healthcare investment platform led by former New Mountain Capital president Matt Holt, has committed $100 million to London-based Penelope Health. Existing backers Bertelsmann Healthcare Investments, Twine Ventures and Seedcamp joined. The funding comes with a partnership to build shared infrastructure for real-time payments and clinical coverage rules. Penelope’s platform tracks insurer coverage policies for more than 200 million Americans across over 15,000 procedure and drug codes. The amount is a commitment rather than a closed round. (Link)
  3. JMI Equity leads Archy’s $50 million Series C, with TCV, Entrée Capital, Bessemer Venture Partners, CRV and Alven participating. JMI Equity led a $50 million Series C in Archy, a San Jose AI platform for running dental practices. Existing investors TCV, Entrée Capital, Bessemer, CRV and Alven joined. Total funding now stands at $97 million. Built-in AI agents handle claims and collections, visit notes, insurance eligibility, patient communications and analytics. Archy serves more than 1,000 practices in 45 states and processes over $300 million in payments a year. (Link)
  4. Catalio Capital Management leads AVAVA’s $45 million financing, made up of $30 million in equity and a $15 million debt facility. Catalio, AVAVA’s first institutional investor, led a $45 million package of $30 million in equity and a $15 million debt facility. The relationship includes $10 million of growth capital from Catalio’s Structured Opportunities Fund in 2024. Boston-based AVAVA sells aesthetic laser devices built on Focal Point Technology, which delivers energy to targeted depths in the skin. The money funds commercial expansion, new products and international growth. (Link)
  5. Obvious Ventures leads Mithrl’s $20 million Series A, with Headline and AGI House participating. Obvious Ventures led a $20 million Series A in Mithrl, a California company building AI infrastructure for drug developers. Headline, AGI House and several pharma executives participated. Its second-generation platform, Mithrl-1, pairs a proprietary biomedical model with agents that choose models and manage cost. It runs inside each client’s environment. The company says top-10 pharma companies and clinical-stage biotechs already use it, with a goal of 50% faster IND timelines. (Link)
  6. Neon leads Ayble Health’s $16 million Series A, with Unum Group (NYSE: UNM)’s Unum Ventures, Upfront Ventures, M13, Ohio-based Cleveland Clinic Ventures, DigiTx and Accomplice participating. Neon led an oversubscribed $16 million Series A in Boston-based Ayble Health. Total capital raised now exceeds $27 million. Ayble runs an AI-enabled virtual clinic for digestive conditions, sold to national health plans, large employers and benefit platforms. It reports a 47% average improvement in symptoms and at least a 3:1 return for customers. The money strengthens AI care tools and expands the company into autoimmune conditions. (Link)
  7. GOA Therapeutics Emerges from Stealth with $15.5 Million; Unveils GOA26 for Acute Alcohol Intoxication Dallas preclinical shop. In an IND-enabling porcine model after 1.2 g/kg oral ethanol, blood alcohol concentration was 61.3% lower versus control at 20 minutes. No FDA-approved drug rapidly lowers BAC today. IND targeted by year-end 2026; first-in-human work in 2027. Data were presented the same day at AAST in Dallas. (Link)
  8. Khosla Ventures leads Nara Health’s $14 million pre-seed and seed financing, with Long Journey Ventures and Superior Studios participating. Khosla led $14 million across pre-seed and seed in Nara Health, formerly Avant Health. Long Journey Ventures, Superior Studios and angels joined. The Chicago company administers health plans for self-insured employers using AI — benefits, claims, care coordination and member support. Nara has more than 25,000 members and has processed over $600 million in claims. CEO Sid Sinha said the money funds Chicago hiring and platform scale. (Link)
  9. Flare Capital Partners leads Kairon Health’s $5 million round, with Tau Ventures, Lightbank, General Advance and Pave Health Ventures participating. Flare led a $5 million round in Kairon Health, joined by Tau Ventures and existing backers Lightbank, General Advance and Pave Health Ventures. Founder Nick Bartz spent nine years at Aledade. The New York AI platform turns claims, records, admission alerts, lab and pharmacy data into task lists for staff at ACOs, health systems and physician groups. It covers more than one million patients across 30-plus states under Medicare, Medicaid and commercial value-based contracts. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 17th, 2026

LECO_Weekly-Healthcare-News_8-17-2026Download

Healthcare Weekly News and Deals

  1. Teledyne Technologies (NYSE: TDY) has entered a definitive agreement to acquire Varex Imaging Corporation (NASD: VREX) for $18.90 per share in cash, valuing the X-ray component maker at approximately $1.1 billion. Teledyne is paying roughly $1.1 billion in cash for Varex, extending a medical imaging build-out that began with the 2011 Teledyne DALSA purchase and the 2017 Teledyne e2v deal. Executive Chairman Robert Mehrabian framed the fit as complementary with minimal overlap: Teledyne lacks detectors for high-radiation oncology environments and photon-counting technology, both of which Varex supplies. Both boards approved unanimously; closing is targeted for early 2027 pending regulatory and Varex shareholder approval. Shareholder litigation is reportedly being weighed over whether the price adequately compensates Varex holders. (Link)
  2. Astorg has completed the carve-out acquisition of Thermo Fisher Scientific’s (NYSE: TMO) global microbiology business Astorg has closed a $1.075 billion carve-out of Thermo Fisher’s microbiology unit, structured as cash plus a $50 million seller note. The asset generated $645 million of 2025 revenue inside Thermo Fisher’s Specialty Diagnostics segment, serving over 15,000 customers across more than 100 countries with roughly 2,400 employees at 13 manufacturing and R&D sites. Judith Charpentier, Co-Managing Partner and Head of Healthcare at Astorg, positioned it as the complex-carve-out profile the firm targets. The business will run independently under CEO Dirk Bontridder and rebrand later in 2026. (Link)
  3. Affordable Care, LLC has completed a recapitalization transferring ownership to its existing lenders, cutting debt by approximately $1.0 billion and injecting $75 million of new capital. Affordable Care, the Morrisville, North Carolina dental support organisation, has closed a balance-sheet restructuring that hands ownership to its lender group. The transaction reduces debt by roughly 65%, or about $1.0 billion, provides $75 million of fresh capital and extends maturities to 2031. This is a creditor-led ownership change rather than a sponsor sale: the incoming lender owners are positioned as aligned with a longer-horizon plan. Deleveraging is intended to free capacity for reinvestment in supported practices, clinical capability, operating infrastructure and patient experience — a familiar reset for over-levered DSO platforms. (Link)
  4. PTC Therapeutics (NASD:PTCT) to acquire ST-920 Fabry disease gene therapy program for $111 million upfront plus milestones PTC Therapeutics has been selected as the winning bidder to acquire ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics in a competitive bankruptcy auction. Terms include $111 million upfront and up to $100 million in contingent regulatory milestones. A rolling BLA submission is expected to be completed in Q4 2026, with potential commercial launch in 2027. The deal leverages PTC’s existing rare disease commercial infrastructure. (Link)
  5. Fulcrum Therapeutics (NASD:FULC) and Slate Medicines announce merger agreement with concurrent $245 million private placement Fulcrum Therapeutics and privately held Slate Medicines have entered a definitive all-stock merger agreement. The combined company will operate as Slate Medicines and focus on next-generation migraine therapies, led by clinical-stage candidate SLTE-1009. Concurrently, Slate secured an oversubscribed $245 million private placement from a syndicate including Frazier Life Sciences, Forbion, RA Capital and others, expected to fund operations into 2029. Closing is targeted for the fourth quarter of 2026. (Link)
  6. EnableComp has acquired Helix Advisory, a Cincinnati, Ohio-based revenue recovery firm, to advance Zero Balance Review technology within its complex revenue recovery platform. EnableComp, the Franklin, Tennessee complex revenue cycle management provider, has acquired Ohio-based Helix Advisory. Terms were undisclosed and both parties are private. The acquisition closes a product gap: EnableComp already recovers roughly $3 billion annually across more than 1,000 hospitals in complex claims and denials, but lacked zero balance review — claims already paid, closed and filed, but paid incorrectly. Helix contributes underpayment detection beyond rules-based logic, clinical signal detection and root-cause analytics, folded into the e360 RCM platform. Founder Zack Higbie joins as VP of Revenue Recovery Products, citing early client net revenue improvements exceeding 2%. (Link)
  7. CHG Healthcare has acquired KREWE Anesthesia, a CRNA-founded staffing firm, to expand certified registered nurse anesthetist staffing and managed anesthesia services. CHG Healthcare, the Salt Lake City-area physician and advanced-practice workforce company, has acquired KREWE Anesthesia. Terms were undisclosed and both parties are private. The investment case rests on scarcity: CHG’s own research ranks CRNAs among the hardest advanced-practice roles to fill nationally, with rural hospitals especially dependent on CRNA-led anesthesia to sustain surgical volume. Founded in 2022, KREWE reports roughly 84% annual clinician retention, materially above locum tenens benchmarks. CEO Leslie Snavely framed the deal as capability plus cultural fit. Founders Gavin Baker and Chase Chiasson remain as CEO and President. (Link)
  8. Viome Life Sciences has acquired Circulate Health, the therapeutic plasma exchange provider, adding clinical delivery to its molecular diagnostics and precision nutrition platform. Viome Life Sciences, the Bellevue, Washington preventive health company founded in 2016, has acquired Circulate Health. Financial terms were not disclosed and both are private. The acquisition converts Viome from a diagnostics-and-recommendations business into one owning the intervention layer, expanding the combined platform to more than 200 partner clinics. Circulate contributes physician-guided therapeutic plasma exchange delivered outside hospital settings, with published research associating its protocol with an average 2.6-year biological age reduction and measurable microplastic reduction. Founder Naveen Jain framed the thesis around measurable, repeatable health improvement. Circulate CEO Brad Younggren becomes president of Viome PRO. (Link)
  9. Kyndryl (NYSE: KD) has agreed to acquire Healthcare IT Leaders, LLC, an enterprise IT services provider to hospitals and health systems, to accelerate AI-led modernization for providers and payors. Kyndryl is buying Healthcare IT Leaders to bolt a consulting and application managed services layer onto its existing infrastructure position in U.S. healthcare. Terms were undisclosed. Jamie Rutledge, president of Kyndryl U.S., framed demand as coming from providers under pressure across clinical, operational and workforce systems while maintaining resiliency and compliance. Strategically, this moves Kyndryl up the stack: it already runs large regulated IT environments, and the target deepens relationships with national health systems across federal, academic, pediatric and regional segments. Closing is expected in Kyndryl’s fiscal 2027 second quarter. (Link)
  10. DermCare Management, LLC and U.S. Dermatology Partners have completed a strategic combination creating one of the largest dermatology group practices in the United States, spanning 12 states. DermCare Management and U.S. Dermatology Partners have closed a combination uniting two physician-led platforms across 12 states. Financial terms were not disclosed and both are privately held. The combined organisation will serve more than three million patients annually — DermCare contributes over 270 providers and more than one million patients across Florida, Texas, Virginia, North Carolina and California, while USDP treats over two million patients across nine states. Scale economics drive the rationale: national clinical trial infrastructure, expanded provider education and shared practice technology. DermCare founder Jeffrey Schillinger becomes Executive Chair; USDP’s Paul Singh leads as President and CEO. (Link)
  11. LLR Partners and LNK Partners-backed Schweiger Dermatology Group has acquired Saratoga Dermatology, expanding its footprint across the greater Albany, New York market. Schweiger Dermatology Group, backed by private equity sponsors LLR Partners and LNK Partners, acquired Saratoga Dermatology on August 5, 2026. Financial terms of the private transaction were not disclosed. The target operates outpatient clinics in Saratoga Springs and Clifton Park under Drs. Jean Buhac, Christopher Heath and John Buhac, delivering medical, surgical and cosmetic dermatology. The sponsors’ model is density plus centralisation: SDG already runs more than 65 offices and roughly 200 providers across the Northeast, and the addition concentrates upstate New York coverage while folding the practice into shared operational infrastructure. (Link)
  12. Little Rock, Arkansas-based Rock Dental Brands has partnered with TLC Pediatric Dentistry & Orthodontics, a Tampa, Florida specialty practice led by Dwight Sanjuan, DMD, and Robertzon Guloy, DMD. Rock Dental Brands has added TLC Pediatric Dentistry & Orthodontics in Tampa, extending its multi-specialty DSO platform into the Florida market. Deal terms were not disclosed and both parties are private. Launched in 2003, TLC pairs pediatric dentistry with orthodontics under two clinician owners, a dual-specialty configuration consolidators favour because it captures a patient across a longer treatment arc and internalises referral flow. Dr. Sanjuan holds memberships in the American Academy of Pediatric Dentistry, the Florida Academy of Pediatric Dentistry and the International Association of Pediatric Dentistry. The transaction reflects continued single-practice tuck-in activity in dental support organisations. (Link)
  13. DuneGlass Capital-backed Phase 1 Equity has acquired a multi-site orthodontic practice in North Dakota, marking its fourth practice addition of 2026 and its 23rd doctor. Phase 1 Equity, the Chicago-headquartered doctor-owned platform launched by DuneGlass Capital in 2022, has added a multi-site North Dakota orthodontic practice. Terms were undisclosed. The transaction is Phase 1’s fourth addition of 2026, its first in North Dakota, and lifts the platform to 23 doctors across 33 locations nationally. The differentiator is the sponsor’s proprietary Doctor Equity model, under which participating orthodontists and pediatric dentists retain full clinical and practice-level decision rights while accessing private-equity economics and network scale. DuneGlass Managing Partner Ryan Graham co-founded the platform as an alternative to conventional dental consolidation. (Link)
  14. WindRose Health Investors, LLC has completed the recapitalization of Verified Clinical Trials, LLC, the clinical trial subject registry provider, and appointed Howard Miller as Chief Executive Officer. WindRose Health Investors, the New York healthcare private equity firm managing roughly $8 billion, has recapitalized Verified Clinical Trials. Terms were undisclosed. Partner CJ Burnes described VCT’s platform as proactively reducing downstream risk across the clinical research chain. The underwriting logic is infrastructure rather than therapeutics: VCT’s secure global database detects duplicate enrolment and protocol violations at screening, and sixteen years of proprietary data assets create a defensible position. Capital funds data and analytics expansion for sponsors, CROs and trial sites. Founders Mitchell Efros, MD and Kerri Weingard, ANP remain actively involved post-close. (Link)
  15. Integrity, LLC has partnered with Meraz Health Insurance Agency, the Temecula, California Medicare-focused independent marketing organization led by Manuel “Manny” Meraz. Integrity, the Dallas-headquartered distributor of life and health insurance and provider of wealth and retirement solutions, has added Meraz Health Insurance Agency to its partner network. Financial details were not disclosed and both parties are private. The transaction follows Integrity’s established roll-up pattern in independent marketing organizations, where acquired agencies gain access to the IntegrityCONNECT AI platform, Ask Integrity voice assistant, marketing infrastructure and carrier breadth. Meraz brings a decade-long Medicare Advantage, prescription drug and Medicare supplement book with deep Latino community distribution — a demographic channel with structural growth in Medicare enrolment. (Link)
  16. Denver-based Mountaingate Capital has fully exited its investment in Relevate Health, the Cincinnati, Ohio-based healthcare commercialization platform, after a six-year partnership. Mountaingate Capital, a lower-middle-market firm partnering with founders and entrepreneurs, has exited Ohio-based Relevate Health, closing August 5, 2026. Terms were undisclosed and the buyer was not identified. Mountaingate first invested in 2020, and the value-creation plan ran through four add-on acquisitions plus investment in Relevate’s proprietary ELE Decision Engine, product suite, infrastructure and leadership team. Co-Founder and Managing Director Bruce Rogers framed the outcome as validation of the original thesis. The firm characterises it as another strong result in tech-enabled, analytics-driven marketing services — a sector where Mountaingate has now realised repeat exits. (Link)
  17. Global systems integrator Myriad360 has acquired the assets of healthcare-focused F3 Technology Partners, pushing the combined platform past the $1 billion annual revenue. Myriad360, the West Deptford, New Jersey-based systems integrator, has purchased the assets of F3 Technology Partners, a West Hartford, Connecticut provider with a longstanding healthcare and financial services vertical. Terms were not disclosed and both are private. The deal follows Myriad360’s February 2026 acquisition of Ohio-based AdvizeX Technologies, which alone created a roughly $900 million run-rate platform; F3 carries the combined business across $1 billion. The strategic driver is channel consolidation — vendor programmes increasingly favour scaled partners, and healthcare vertical depth commands premium positioning in a fragmented integrator market. (Link)
  18. Gridiron Capital, LLC has partnered with van den Boom & Associates, the San Diego-based outsourced back-office services provider to emerging life sciences companies, under founder Esther van den Boom’s continued leadership. Gridiron Capital, the New Canaan, Connecticut firm focused on founders, entrepreneurs and management teams, has invested in van den Boom & Associates. Financial terms were not disclosed. The deal advances Gridiron’s Outsourced Pharma Services Thematic Area of Expertise and builds on prior healthcare and pharma-adjacent services investments. Principal Aaron Stoppelmann framed the thesis around two converging trends: growth in venture-backed life sciences companies and their preference for specialised operational partners. vdB&A serves 160-plus active clients with 150-plus professionals across finance, HR, contract management, compliance and a newly launched IT managed services line. (Link)
  19. Marlin Equity Partners-backed Radar Healthcare has acquired patient experience and patient-reported outcomes platform Cemplicity, following its earlier purchase of EIDO Healthcare. Radar Healthcare, the quality, risk and compliance software provider backed by Marlin Equity Partners, has acquired Cemplicity. Terms were undisclosed and both parties are private. The sponsor thesis is adjacency stacking rather than scale: Cemplicity contributes patient experience measurement, patient-reported outcomes and real-time patient insight, which Radar pairs with its existing quality, risk and improvement workflows. Chief Executive Edward Bellamy positioned the logic as connecting what patients report to the workflows needed to act on it. The deal follows Radar’s acquisition of digital consent provider EIDO Healthcare, extending a buy-and-build across the quality-and-safety software stack. (Link)
  20. The Riverside Company adds Yellow Emperor to Western Botanicals The Riverside Company has made Yellow Emperor its first add-on investment for portfolio company Western Botanicals. The Eugene, Oregon-based CDMO specializes in custom liquid dietary supplement formulations, providing end-to-end services from ingredient sourcing through manufacturing, bottling and packaging. The combination deepens Western Botanicals’ liquid capabilities and strengthens its position as a formulator and manufacturing partner for health and wellness brands. (Link)
  21. Sarnova, Patricia Industries portfolio company, acquires Mercury Medical Sarnova, a national specialty distributor of emergency medical services and acute care products, has acquired Mercury Medical. The Clearwater, Florida-based company designs, manufactures and distributes critical care and emergency medical devices. The deal expands Sarnova’s product portfolio across its Bound Tree Medical, Cardio Partners, Emergency Medical Products and Tri-anim Health Services units. (Link)
  22. Livingbridge has put teleradiology group Everlight Radiology up for sale at around $1 billion, with Radiology Partners reported to be the front-runner UK mid-market firm Livingbridge is running a roughly $1 billion sale of Everlight Radiology. The process is now in its late stages, with Radiology Partners reported to be leading. An Everlight exit would hand Livingbridge a large realisation from a cross-border teleradiology asset, while a Radiology Partners win would extend the US-based radiology platform’s reach into Australian and UK night-hawking volumes. Radiology reading remains one of the most actively consolidated healthcare services niches for private capital. (Link)
  23. Curium acquires Abscint, expanding its PET radiodiagnostic pipeline in oncology Curium, a global radiopharmaceutical company, has completed the acquisition of Abscint SA, a Belgian clinical-stage company developing PET imaging agents for oncology. The deal adds ABS-011, an investigational gallium-68-labeled PET tracer targeting HER2 that is currently in a Phase 2b trial. Curium gains global rights to develop, manufacture and commercialize the asset, strengthening its radiodiagnostic capabilities in breast and gastric cancers. (Link)

Venture Deals and Other

  1. Soleus Capital has led a $110 million Series C and debt financing in Bridge to Life Ltd., with Lauxera Capital Partners participating and Soleus Capital Credit Opportunities Fund providing the debt tranche. Soleus Capital, the Greenwich firm with roughly $3.5 billion in assets under management, led the equity alongside Lauxera Capital Partners, which manages over $1 billion across 14 healthtech portfolio companies; Bridge to Life directors, officers and employees also participated. Partner Ben Lund cited the pairing of an established preservation franchise with a newly FDA-cleared perfusion platform. Proceeds refinance the Perceptive Credit Funds facility — cutting leverage and interest cost — and fund the VitaSmart HOPE System commercial build-out to every U.S. transplant center, plus a viability assessment tool and multi-organ pipeline. (Link)
  2. Bessemer Venture Partners has led a $50 million Series B in Flagler Health, with participation from SignalFire, Alumni Ventures, Streamlined, 186 Ventures, Proof VC, Tribeca Venture Partners and Offscript. Bessemer Venture Partners led the $50 million Series B for New York-based Flagler Health, taking total funding to $63 million. Partner Steve Kraus pointed to the founding team’s combination of healthcare operations experience, clinical authority and AI expertise applied to a large underserved market. Investors are backing demonstrated unit economics rather than promise: in under three years Flagler has scaled to thousands of providers across more than 36 states, delivering an average $164,000 in additional annual revenue per provider, with 87% of patients reporting improvement. Musculoskeletal care represents over $400 B in annual U.S. spend. (Link)
  3. OG Venture Partners and M Ventures, the corporate venture arm of Merck KGaA, Darmstadt, Germany (ETR: MRK), have co-led a $36 million Series A in Remepy, joined by NFX, Qumra Capital, Tadmor Group, TechAviv and Vine Ventures. OG Venture Partners and M Ventures, the strategic venture arm of Merck KGaA (ETR: MRK), led Remepy’s $36 million Series A, lifting total capital raised to $62 million. The strategic investor’s participation is notable given Merck KGaA’s existing hybrid drug development partnership with Remepy covering multiple indications, starting with rare tumours. Proceeds fund a global Phase III trial of lead asset Hybridopa in Parkinson’s disease, commencing in the fourth quarter of 2026, following positive Phase IIa motor and non-motor data. Investors are betting on evolving U.S. regulatory frameworks for drug-software combination products. (Link)
  4. Redmile Group, Vsquared Ventures and Kindred Capital have co-led a $25 million seed round in Bios Life, which signed a multi-year data alliance with Tempus AI (NASD: TEM). Redmile, Vsquared Ventures and Kindred Capital led the $25 million seed for Bios Life, joined by healthcare and technology investors across the United States and Europe — an unusually deep syndicate for a company emerging from stealth. Investors are underwriting a founder-pedigree and data-moat thesis: CEO Ryan Richardson was BioNTech’s chief strategy officer and chaired InstaDeep, and the company holds commercial rights to the Nucleotide Transformer genomics foundation model. The Tempus alliance supplies de-identified multi-modal oncology data for training, with Tempus-owned Ambry Genetics adding hereditary testing. Launch is slated for second-half 2026. (Link)
  5. Battery Ventures has made a significant growth investment in Vetspire, the AI operating system for veterinary practices, carving it out as a standalone company from Thrive Pet Healthcare. Battery Ventures, a global technology-focused investment firm founded in 1983, is backing Vetspire as an independent business, with Thrive Pet Healthcare retaining no ownership going forward while remaining a long-term customer. Terms were undisclosed. General Partner Chelsea Stoner cited timing: Covid-era adopted pets are aging into higher care needs. Battery brings a track record in specialty-healthcare EHR and practice-management platforms including Brightree, ClearCare, ContinuumCloud, Curve Dental and WebPT. Vetspire runs at more than 800 hospitals and clinics; Zachary Seely joins as CEO. (Link)
  6. XiFin, Inc. has made a strategic investment in Denver-based Notable Systems as part of Notable’s Series B financing, alongside a multi-year agentic AI alliance across revenue cycle management. XiFin has invested in Notable Systems’ Series B while committing to a multi-year technology alliance. The investment amount was not disclosed and both companies are private. Executive Chair and CEO Lâle White framed the capital commitment as reinforcing XiFin’s position in intelligent revenue cycle management. Notable’s document intelligence will be embedded into the XiFin Empower AI RCM ecosystem, targeting requisitions, prescriptions, medical records and payer correspondence. Notable serves enterprise DME providers including Orthofix (NASD: OFIX) and National Seating & Mobility. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update July 13th, 2026

LECO_Weekly-Healthcare-News_7-13-2026Download

Healthcare Weekly News and Deals –July 13th, 2026

  1. American Industrial Partners agreed to acquire Avanos Medical (NYSE: AVNS) in an all-cash take-private valued at approximately $1.272 billion. American Industrial Partners (AIP), an operationally oriented investor with roughly $17.8 billion in assets, is acquiring Avanos Medical (NYSE: AVNS) for $25.00 per share in cash — a ~72% premium to Avanos’s pre-announcement close — valuing the medical-technology company at about $1.272 billion enterprise value. Having cleared regulatory review, the deal is expected to close by late July 2026 following a July 22 stockholder vote. Alpharetta, Georgia-based Avanos, focused on specialty nutrition and pain-management/recovery devices, will become privately held. AIP plans to leverage its operational playbook to support Avanos’s next phase of innovation and commercial execution. (Link)
  2. TCW Steel City (part of PNC Financial Services Group, NYSE: PNC), alongside co-lenders Brightwood, CIFC and CalSTRS, provided a $170 million recapitalization financing to Colorado-based Lone Peak Dental Group. TCW Steel City — the private-credit platform combining PNC Financial Services Group (NYSE: PNC) and TCW Private Credit — served as lead arranger and administrative agent on a $170 million recapitalization of Lone Peak Dental Group, a Dental Partnership Organization operating 75-plus offices across 14 states. The facility bundled a term loan, revolver and delayed-draw term loan structured to bankroll future acquisitions. Brightwood, CIFC and CalSTRS joined as additional lenders. The senior-secured package reflects private-credit appetite for scaled, mission-driven dental platforms pursuing both de novo and affiliation growth, giving Lone Peak flexible capital to expand pediatric dental access across its footprint. (Link)
  3. Surplus Solutions, a portfolio company of private equity firm NMS Capital, acquired Frederick, Maryland-based DCM BioServices to expand its laboratory-automation technical-service capabilities. NMS Capital, a private equity firm managing more than $2.0 billion across business and healthcare services, added to its Surplus Solutions platform with the acquisition of DCM BioServices, a Frederick, Maryland provider of lab-automation maintenance, repair and integration. Terms were undisclosed. The tuck-in extends Surplus Solutions’ equipment-lifecycle-management model into recurring preventive-maintenance contracts — a stream NMS partner David Peterson framed as a natural extension of existing customer relationships. DCM services 3,000-plus instruments across 200-plus labs nationwide, deepening the platform’s technical bench across leading instrument makers and reinforcing NMS’s buy-and-build thesis in life-sciences services. (Link)
  4. Orthopedic & Balance Therapy Specialists, a seven-clinic Northwest Indiana outpatient physical-therapy practice, was sold to an undisclosed national rehabilitation platform. Orthopedic & Balance Therapy Specialists (OBTS), a seven-location outpatient physical-therapy provider founded in 2003 in Northwest Indiana, completed a sale to an unnamed national rehabilitation platform. Both financial terms and the acquiring platform were left undisclosed. The transaction fits the broader private-equity-driven consolidation of outpatient rehab, where scaled platforms continue absorbing founder-owned, multi-clinic practices with strong payer relationships and regional density. OBTS’s shareholders sought a strategic partner to preserve clinical standards and culture while accessing platform resources for continued growth, positioning the practice to expand within its market under larger ownership. (Link)
  5. EQT (Nasdaq Stockholm: EQT), through its EQT X fund, agreed to acquire the Corza Biosurgery/TachoSil business from Corza Medical, which is backed by private equity firm GTCR. EQT (Nasdaq Stockholm: EQT) agreed to acquire Corza Biosurgery — built around TachoSil, a dual-action hemostat-and-sealant surgical patch — from GTCR-backed Corza Medical. Financial terms were undisclosed; closing is expected in Q4 2026. Investing through its EQT X fund, EQT plans to accelerate U.S. commercial and indication expansion, broaden adoption in underpenetrated markets, and build a wider biosurgery platform via add-on M&A. GTCR, which carved out TachoSil in 2021 and combined it with Surgical Specialties, exits the unit. TachoSil is used across cardiovascular, hepatic, neurological and thoracic procedures in more than 50 countries. (Link)
  6. Onto Health, a fertility and longevity platform backed by ARTIS Ventures and Humania, acquired U.S.-based clinical-decision-support company LEVY Health. Onto Health — a physician-led fertility and longevity provider backed by ARTIS Ventures and Humania — acquired LEVY Health, a U.S. clinical-decision-support software company for reproductive medicine. Terms were undisclosed. The purchase follows Onto’s roughly $20 million Series A and provides the technological backbone for a scalable, tech-enabled fertility-care infrastructure spanning the United States and the Gulf Cooperation Council region. LEVY’s diagnostics help clinics identify endocrine disorders and streamline fertility workups, letting practices fold low-complexity fertility care into existing models. The deal signals investor appetite for AI-enabled infrastructure plays in the multi-billion-dollar global fertility-services market. (Link)
  7. ResMed (NYSE: RMD) agreed to sell its MatrixCare software business to private equity firm Frazier Healthcare Partners for $490 million in cash. ResMed (NYSE: RMD) agreed to divest its MatrixCare post-acute-care software unit to Frazier Healthcare Partners, a healthcare-focused private equity firm, in a $490 million all-cash deal expected to close in the first quarter of ResMed’s fiscal 2027. ResMed, which paid $750 million for MatrixCare in 2018, will redeploy proceeds toward shareholder returns via an accelerated share repurchase while sharpening its sleep-and-breathing focus. MatrixCare — serving 15,000-plus skilled-nursing, senior-living and home-health providers — generated roughly $220 million revenue and $55 million adjusted operating profit in fiscal 2026. Frazier, which has raised over $11 billion, gains a scaled long-term-care software platform. (Link)
  8. Steel Partners Holdings (NYSE: SPLP), a shareholder of InMode (NASDAQ: INMD), offered to acquire the medical-aesthetics company for $16.75 per share in cash, topping a competing CEO-led bid. Steel Partners Holdings (NYSE: SPLP), which owns roughly 1.3% of InMode (NASDAQ: INMD), launched an unsolicited $16.75-per-share all-cash offer for the Israeli medical-aesthetics maker — a 20% premium to the $13.95 unaffected price and $0.55 above a rival buyout led by CEO Moshe Mizrahy. Steel argued the CEO’s $16.20 bid undervalued InMode using a low 2026 EBITDA estimate, demanded Mizrahy’s removal over governance conflicts, and urged the board to form an independent committee. Steel also offered existing holders the option to roll up to 40% of their equity into the privatized company, intensifying the contested sale process. (Link)
  9. Emergency Care Partners — backed by private equity firms Varsity Healthcare Partners, MidOcean Partners and Regal Healthcare Capital Partners — partnered with Phoenix-based Empower Emergency Physicians. Emergency Care Partners (ECP), the largest single-specialty emergency-medicine physician-services provider in the U.S. and backed by Varsity Healthcare Partners, MidOcean Partners and Regal Healthcare Capital Partners, formed a strategic partnership with Empower Emergency Physicians, a Phoenix independent group serving Dignity Health’s St. Joseph’s hospitals. Terms were undisclosed. The deal extends Pensacola-based ECP’s Southwest footprint to more than 1.7 million annual patient encounters across ten states while preserving Empower’s physician-led model. It reflects the sponsors’ buy-and-build strategy of consolidating physician-owned groups under ECP’s infrastructure, building on MidOcean’s 2025 preferred-equity investment that funds continued acquisitions. (Link)
  10. Incline Equity Partners acquired a majority stake in medical and health physics testing provider West Physics from LNC Partners, which retains a minority interest. Incline Equity Partners acquired a majority equity interest in Atlanta-based West Physics, a provider of medical and health physics testing and consulting that certifies MRI, CT and X-ray equipment against ACR, IAC and Joint Commission standards across 6,000-plus client sites in all 50 states and abroad. Terms were undisclosed. Seller LNC Partners — which first invested in May 2018 and grew revenue more than 3.7x over seven years through organic expansion and six add-on acquisitions — rolls over a minority position alongside Incline. Founder-CEO Dr. Geoffrey West continues to lead, with both sponsors backing further organic growth and M&A into adjacent services and geographies. (Link)
  11. Cygnet Group, backed by parent company Universal Health Services (NYSE: UHS), acquired Orchard Care Group in the Republic of Ireland. Cygnet Group — the UK mental-health and social-care provider owned by Universal Health Services (NYSE: UHS) — acquired Orchard Care Group, an integrated fostering, residential and disability-care provider in the Republic of Ireland. Terms were undisclosed. Orchard operates 39 residential and community homes plus two day services and employs over 550 people, with its executive team staying on. The deal marks Cygnet’s first residential-support expansion beyond the UK, extending UHS’s international social-care reach. It follows Cygnet’s recent run of UK acquisitions and hospital builds, signaling continued consolidation of specialist care assets under the publicly traded U.S. hospital operator. (Link)
  12. HCC Healthcare signed a business-combination agreement with SPAC RF Acquisition Corp III (Nasdaq: RFAM) to pursue a Nasdaq listing at a roughly $500 million equity value. Singapore-incorporated HCC Healthcare, which runs integrated medical and long-term-care services through Taiwan subsidiaries, agreed to merge with RF Acquisition Corp III (Nasdaq: RFAM), a publicly traded special-purpose acquisition company, to go public on Nasdaq. The deal reflects a pre-transaction equity value of approximately $500 million at $10.00 per share, with closing targeted for Q4 2026 subject to shareholder and regulatory approvals. On a pro forma basis, the combined Taiwan-focused network spans 120-plus long-term-care facilities and 9,000-plus beds. The SPAC route gives HCC public-market capital to scale its aging-population care model across Taiwan, Japan and Asia. (Link)
  13. Austin, Texas-based private equity firm CenterGate Capital invested in Canadian Dental Labs (CDL), Canada’s leading manufacturer of dental prosthetics and orthodontic appliances. CenterGate Capital, an Austin, Texas private equity firm, made a control investment in Canadian Dental Labs (CDL), the Toronto-headquartered platform that is Canada’s leading maker of dental prosthetics and orthodontic appliances. Terms were undisclosed. CDL — comprising labs including Shaw Lab Group, Protec Dental and Hallmark — serves 5,000-plus dental professionals and DSOs nationwide, with CEO Ali Rezaei continuing to lead. CenterGate backs the platform’s next growth phase, funding investment in people, technology and its coast-to-coast laboratory network. The deal underscores private equity’s appetite for scaled, technology-forward dental-lab consolidators with recurring, patient-specific manufacturing demand. (Link)
  14. ReFocus Eye Health, the management-services organization backed by Zenyth Partners, partnered with Connecticut’s 11-location Solinsky EyeCare. ReFocus Eye Health — a Northeast ophthalmology management-services organization backed by investment firm Zenyth Partners — affiliated with Solinsky EyeCare, an 11-location comprehensive ophthalmology and optometry practice serving Greater Hartford, Connecticut. Terms were undisclosed. Adding Solinsky’s 14 ophthalmologists and optometrists lifts ReFocus’s network to more than 250 affiliated physicians across 114 locations in nine states. The affiliation preserves physicians’ clinical autonomy while providing operational and administrative support, reflecting Zenyth-backed ReFocus’s continued regional roll-up strategy. The transaction adds to a wave of private-equity-sponsored consolidation in eye care as platforms pursue density in attractive Northeastern markets. (Link)
  15. CONMED Corporation (NYSE: CNMD) is weighing a potential sale after receiving takeover interest from unnamed private equity firms. CONMED Corporation (NYSE: CNMD), a surgical-device maker focused on orthopedic and general surgery, saw shares jump as much as 10% after Bloomberg reported the company is exploring strategic options following acquisition interest from private equity firms. No formal sale process has been confirmed and specific bidders have not been disclosed. CONMED, whose products include sports-medicine implants, electrosurgery systems and the AirSeal platform, has been sharpening its focus on higher-margin surgical segments after exiting gastroenterology lines. The reported interest highlights sustained private-equity appetite for scaled medtech assets, though any transaction remains speculative pending confirmation of a formal review. (Link)
  16. Clarivate Plc (NYSE: CLVT) agreed to sell its Life Sciences & Healthcare segment to healthcare-focused investment firm Altaris LLC for $600 million. Clarivate Plc (NYSE: CLVT) agreed to divest its Life Sciences & Healthcare segment to Altaris LLC, an investment firm focused exclusively on healthcare, for $600 million. Clarivate receives $500 million cash at closing plus $25 million deferred, using proceeds to cut debt and sharpen its subscription-first focus on Academia & Government and Intellectual Property. The company expects a $225–250 million non-cash goodwill impairment. For Altaris, the carve-out delivers a data-and-analytics platform supporting decision-making across the drug and device lifecycle. The transaction reflects the recurring theme of publicly traded information providers shedding non-core units to specialist private-equity buyers. (Link)
  17. Private equity firm Warburg Pincus, partnering with the Abu Dhabi Investment Authority, is nearing a $7 billion-plus acquisition of specialty pharmacy PANTHERx Rare from owners General Atlantic, Nautic Partners and The Vistria Group. Warburg Pincus, which manages over $100 billion, is in advanced talks to acquire Pittsburgh-based specialty pharmacy PANTHERx Rare for more than $7 billion including debt, partnering with sovereign-wealth fund the Abu Dhabi Investment Authority. PANTHERx, focused on rare and orphan-disease medicines and patient support, is owned by a consortium of General Atlantic, Nautic Partners and The Vistria Group, which bought it from Centene in 2022. Nothing is finalized and timing could slip. The deal reflects private equity’s bet on recession-resistant, high-margin orphan-drug demand and the growing pattern of buyout firms pairing with sovereign-wealth capital on large checks. (Link)
  18. Halma plc (LSE: HLMA) acquired Summit Partners-backed Dreampath Diagnostics for an initial €154 million plus an earn-out of up to €121 million. UK-listed Halma plc (LSE: HLMA) acquired Dreampath Diagnostics, a Strasbourg-based provider of automated tissue-sample management systems for pathology labs, from growth-equity firm Summit Partners. Halma is paying an initial €154 million (about $132 million) in cash, with a performance-based earn-out of up to €121 million through 2028. Summit, which made an undisclosed growth investment in 2025, exits after helping Dreampath scale to 300-plus million samples across 500-plus labs in 50 countries. Dreampath — forecasting roughly €33 million revenue for the year to March 2027 — will run standalone within Halma’s Healthcare Sector, strengthening its diagnostics traceability capabilities. (Link)
  19. Spero Health — backed by Heritage Group, Health Velocity Capital, South Central Inc. and Frist Cressey Ventures — acquired CleanSlate Centers, backed by Granite Growth Health Partners, HealthQuest Capital and CRG. Spero Health, a Nashville-area outpatient addiction-treatment provider owned by Heritage Group, Health Velocity Capital, South Central Inc. and Frist Cressey Ventures, acquired multi-state opioid-treatment operator CleanSlate Centers — backed by Granite Growth Health Partners, HealthQuest Capital and CRG — in a deal that closed July 1 and averts CleanSlate’s shutdown. Spero assumed CleanSlate’s equity interests in exchange for taking on its debt and deal costs; terms were undisclosed. The combination roughly doubles Spero’s footprint to 128 locations across ten states, with heavy overlap in Ohio, Indiana and Kentucky, reflecting Spero’s thesis that consolidation strengthens payer leverage. (Link)
  20. Private equity firm Enhanced Healthcare Partners made a growth investment in LeadingReach, healthcare’s largest connected referral network. Enhanced Healthcare Partners (EHP), a healthcare-focused private equity firm, made a growth investment in Austin-based LeadingReach, operator of healthcare’s largest verified referral network spanning 30,000-plus organizations, 60,000-plus care settings and 125,000-plus providers processing 25,000 daily referrals. Terms were undisclosed. EHP adds experienced healthcare operators to LeadingReach’s board and provides resources to accelerate AI-powered automation, deeper EHR integrations and expanded network infrastructure following the company’s recent acquisition of iNaira Healthcare Technologies. The investment reflects EHP’s focus on founder-led health-IT platforms positioned to benefit from the industry’s shift toward value-based care and referral coordination. (Link)
  21. Shore Capital Partners, a healthcare-focused private equity firm, acquired Denver-based employee-benefits technology platform ThrivePass. Shore Capital Partners, a Chicago-based private equity firm with roughly $17 billion in assets, acquired ThrivePass, a Denver employee-benefits administration technology platform founded by Wade Rosen, Andreas Deptolla and Charles Shen. Terms were undisclosed. The investment funds continued development of ThrivePass’s configurable platform — spanning lifestyle spending accounts, rewards, tuition reimbursement, COBRA and pre-tax benefits for employers, brokers and PEOs. Shore brings healthcare-focused operational resources and a consolidation playbook to scale the business as demand grows for digital-first benefits tools. The deal extends Shore’s health-tech portfolio, targeting a lower-middle-market platform with organic and acquisition-driven growth potential. (Link)
  22. Integrity, LLC acquired Stride Health, the portable-benefits technology platform powering gig-economy insurance enrollment for partners including Uber, DoorDash and Amazon Flex. Dallas-based insurance distributor Integrity, LLC acquired Stride Health, a San Francisco portable-benefits technology platform that helps independent and gig workers enroll in health, dental, vision and life coverage. Terms were undisclosed. Stride — founded in 2014 and previously Allstate-backed — connects 4.6 million-plus workers and 140-plus enterprise partners including Uber, DoorDash, Gusto and Amazon Flex. Integrity folds Stride’s consumer marketplace into its IntegrityCONNECT agent platform and roughly 600,000-strong agent network, expanding into the under-65 individual market where tens of millions lack employer coverage. The deal pairs digital enrollment with agent-assisted distribution as worker-misclassification rules reshape portable-benefits demand. (Link)
  23. Principal Financial Group (Nasdaq: PFG) agreed to acquire digitally-native ancillary employee-benefits company Beam Benefits to expand its small-business protection platform. Principal Financial Group (Nasdaq: PFG) agreed to acquire Beam Benefits, a cloud-native ancillary employee-benefits company serving over 25,000 small businesses with dental, vision, life, disability and supplemental health coverage. Terms were undisclosed. Beam — built on an AI-powered underwriting and self-service technology stack and available in 46 states plus D.C. — generated roughly $175 million in premiums in 2025. Principal, which serves 180,000 employers, expects the deal to close in the latter half of 2026 and to lift Specialty Benefits premium and fee growth to at or above the high end of its 5–9% medium-term target in 2027. The digital-first model adds scalable capabilities to Principal’s SMB strategy. (Link)

Venture Deals and Other

  1. Valspring Capital led a $28 million Series B in Pediatrica Health Group, with participation from existing investor M33 Growth. Pediatrica Health Group, a Miami-based multi-site pediatric primary-care organization, closed a $28 million Series B led by Boston growth-equity firm Valspring Capital, with existing backer M33 Growth participating. The capital funds organic growth and strategic acquisitions plus investment in clinical infrastructure, technology and value-based-care capabilities. Pediatrica — founded through its partnership with M33 — has scaled to 21 locations across Florida and Texas. Valspring, formed by Bain Capital Ventures’ former healthcare team, cited its thesis that lasting healthcare change comes from companies innovating on patient and provider experience. The round backs continued expansion of equitable pediatric primary-care access. (Link)
  2. RPS Ventures led a $19 million Series B in Handspring Health, with new investor Angelini Ventures joining returning backers Cobalt Ventures, NextView Ventures, nvp capital, Hyde Park Angels and Cornucopian Capital. Handspring Health, a virtual youth mental-health provider, raised a $19 million Series B led by RPS Ventures, with new investor Angelini Ventures joining returning backers Cobalt Ventures, NextView Ventures, nvp capital, Hyde Park Angels and Cornucopian Capital. The round — lifting total funding to $37 million — funds clinician hiring, deeper value-based-care partnerships with payers, broader geographic reach and technology investment. Handspring, which employs rather than contracts its therapists and trains them in-house in evidence-based modalities, has treated 4,000-plus patients across nine states and grown revenue more than tenfold in two years. RPS’s Nancy Hilliker joins the board. (Link)
  3. Surface Ventures led a $3 million seed round in Octozi, with participation from Remarkable Ventures and following a prior investment from Debiopharm’s venture arm. Octozi, a New York agentic-AI company automating clinical-trial data operations for pharmaceutical sponsors, raised $3 million in seed funding led by Surface Ventures, with Remarkable Ventures participating and building on an earlier stake from Swiss pharma Debiopharm’s venture arm. The capital expands Octozi’s human-in-the-loop platform, which integrates with clinical systems to automate data cleaning, reconciliation, review and reporting. A peer-reviewed study found the tool boosted data-cleaning throughput roughly sixfold and cut reviewer error rates from about 55% to 8%, with estimated savings above $5 million per Phase III oncology trial. Surface Ventures’ Gyan Kapur framed the bet on compressing drug-development timelines. (Link)
  4. Andreessen Horowitz led a $50 million equity round for Pearl Health, joined by Viking Global Investors, AlleyCorp and Ulysses Capital, alongside a $60 million debt facility led by Trinity Capital (NASDAQ: TRIN). Pearl Health, a New York health-technology company enabling providers to manage risk for Medicare patients, raised $110 million — a $50 million equity round led by Andreessen Horowitz with Viking Global Investors, AlleyCorp and Ulysses Capital, plus a $60 million debt facility led by Trinity Capital (NASDAQ: TRIN). The capital funds AI-platform expansion, new risk products, Medicare Advantage entry and enterprise health-system and payer partnerships. Pearl — profitable in 2025 — supports 10,000-plus providers across 40-plus states serving 250,000-plus beneficiaries and manages roughly $3.6 billion in annualized medical spend. a16z’s Vineeta Agarwala praised Pearl’s technology-led approach to value-based payment. (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update May 25th, 2026 – Happy Memorial Day!

LECO_Weekly-Healthcare-News_5-25-2026Download
  1. Oura Inc. (ŌURA) submits confidential draft Form S-1 to the SEC for a proposed initial public offering of its common stock. San Francisco-based Oura Inc., the smart-ring maker behind the Oura Ring, has confidentially submitted a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range have not yet been determined, with the IPO expected after the SEC completes its review. Oura was valued at $11 billion in October 2025 following a $900 million Series E and is projected to generate roughly $2 billion in 2026 revenue. The company supports over 1,200 wellness and medical partners. (Link)
  2. Medtronic (NYSE: MDT) to Acquire SPR Therapeutics for $650 Million Medtronic plc has agreed to acquire SPR Therapeutics, a pioneer in minimally invasive peripheral nerve stimulation (PNS) technology, in an all-cash transaction valued at $650 million. The deal brings in SPR’s FDA-cleared SPRINT PNS System, a temporary, non-opioid solution for chronic pain that has demonstrated strong clinical outcomes with lower risk compared to permanent implants. For Medtronic, this bolsters its neuromodulation portfolio and accelerates its shift toward less invasive, drug-free pain management therapies amid growing demand for opioid alternatives. The acquisition is expected to close in the first half of Medtronic’s fiscal 2027 and should be immediately accretive to earnings. (Link)
  3. Eli Lilly and Company (NYSE: LLY) Acquires Engage Bio to Accelerate Development of Non-Viral Genetic Medicines Eli Lilly and Company has acquired Engage Bio, a preclinical biotechnology company focused on non-viral delivery platforms for genetic medicines. The deal provides Lilly with proprietary technology aimed at improving the safety and efficacy of gene editing and RNA-based therapies. Engage Bio’s platform is designed to overcome key limitations of current viral vector approaches, potentially enabling broader application of genetic medicines. This acquisition reinforces Lilly’s commitment to building leadership in next-generation genetic medicine platforms. (Link)
  4. BrainsWay Ltd. (NASD: BWAY; TASE: BWAY) invests $1.5M for a minority stake in Hopemark Health, operated by Advanced Psychiatric Management LLC under parent APS Innovations LLC. Burlington, Mass.-based BrainsWay Ltd. (NASDAQ: BWAY; TASE: BWAY) has entered a strategic equity financing agreement with APS Innovations LLC, the parent of Advanced Psychiatric Management LLC, which operates Chicago-area mental health clinics under the Hopemark Health brand. BrainsWay is investing $1.5 million for a minority position via a preferred, annually compounding security, with the potential for an additional $1.5 million through milestone-based investments and a redemption mechanism. CEO Hadar Levy described the deal as part of BrainsWay’s strategy to partner with growth-oriented clinical platforms and expand access to interventional psychiatry solutions including Deep TMS. BrainsWay is valued at roughly $606 million. (Link)
  5. QT Imaging Holdings, Inc. (NASD: QTI) closes a $10M underwritten public offering with both existing and new investors participating. Novato, Calif.-based QT Imaging Holdings, Inc. (NASDAQ: QTI) has completed an underwritten public offering of 2,000,000 shares of common stock or pre-funded warrants, generating gross proceeds of approximately $10 million. The offering was priced at $5.00 per share, with pre-funded warrants at $4.9999, and saw participation from both existing and new investors. Net proceeds will be used for working capital and general corporate purposes. QTI shares had declined 24% over the week prior to closing, trading at $5.49 with a market capitalization of $65.63 million. QT Imaging develops radiation-free, ultrasound-based breast imaging technology and recently posted strong Q1 2026 revenue growth. (Link)
  6. Innovaccer Inc. acquires CaduceusHealth (reported at $66M) to build out its agentic revenue cycle management platform. San Francisco-based healthcare AI company Innovaccer Inc. has acquired CaduceusHealth, a nationally recognized revenue cycle management services provider, in a reported $66 million asset deal — Innovaccer’s fifth strategic acquisition. Founded in 1997, CaduceusHealth manages billing, claims, and denial resolution for nearly 4,000 providers and handles $5 billion in gross patient charges annually across every major EHR. The transaction expands Innovaccer’s Flow suite into full-stack RCM capabilities, unifying scheduling, patient engagement, and end-to-end revenue cycle workflows for ambulatory care providers. The integrated platform leverages Innovaccer’s Gravity AI infrastructure to address the nearly $20 billion lost annually to avoidable denials. (Link)
  7. Nexalin Technology, Inc. (NASD: NXL) acquires PONM, Inc. from GreenLight Ventures, LLC for $1.3M in stock. Houston-based Nexalin Technology, Inc. (NASDAQ: NXL) has closed the acquisition of PONM, Inc. from GreenLight Ventures, LLC for $1.3 million payable in Nexalin common stock issued across four tranches, with 959,016 shares delivered at closing. PONM is the AI-integrated digital health platform powering Nexalin’s HALO Clarity neurostimulation program and Nexalin NeuroCare virtual clinic, already deployed at UC San Diego. Nexalin gains ownership of PONM and an exclusive license to proprietary software for remote patient monitoring, EHR functionality, and virtual-clinic management. GreenLight becomes a significant Nexalin equity holder and continues engineering, cybersecurity, and regulatory support under a 24-month collaboration agreement. (Link)
  8. GHO Capital and CBC Group Merge to Create $21 Billion Global Healthcare Investment Platform GHO Capital and CBC Group have completed a transformational merger to form one of the world’s largest dedicated healthcare private equity firms with over $21 billion in assets under management. The combined platform brings together GHO’s European mid-market expertise with CBC’s strong Asia-Pacific presence and deep sector relationships. The merger significantly enhances the firm’s ability to pursue larger transactions and cross-border opportunities across healthcare services, biotech, and medtech. For limited partners, this creates a truly global healthcare investor with greater scale, sourcing advantages, and operational resources. (Link)
  9. Grundium (backed by EW Healthcare Partners) Acquires Visiopharm to Create Integrated Precision Pathology Platform Grundium Oy, backed by EW Healthcare Partners, has acquired Visiopharm A/S, a leader in AI-powered image analysis software for digital pathology. The strategic combination merges Grundium’s high-quality digital slide scanners with Visiopharm’s advanced AI algorithms for automated tissue analysis and biomarker quantification. The deal creates a comprehensive end-to-end precision pathology solution that improves diagnostic accuracy, reduces turnaround times, and supports pathologists facing increasing workloads. For investors, this positions the combined platform to capture significant share in the rapidly growing computational pathology market driven by oncology and personalized medicine. (Link)
  10. Cohere Acquires Reliant AI to Expand Sovereign Enterprise AI for Biopharma and Healthcare Cohere has acquired Reliant AI, a biopharma-specialized AI company with operations in Montreal and Berlin. The transaction strengthens Cohere’s vertical AI capabilities in regulated industries by integrating Reliant’s domain-specific models optimized for clinical, regulatory, and research workflows. This move enhances Cohere’s ability to deliver sovereign, privacy-compliant AI solutions for large pharmaceutical and healthcare enterprises. The acquisition underscores the accelerating trend of big tech players deepening vertical specialization to address the unique data governance and compliance requirements of life sciences. (Link) (Link)
  11. Pillr Health (backed by Water Street Healthcare Partners) acquires CaptureRx for undisclosed terms to expand its 340B pharmacy solutions platform. Boca Raton, Fla.-based Pillr Health — a 340B-focused pharmacy optimization platform recently acquired by Water Street Healthcare Partners from Renovus Capital Partners — has acquired San Antonio-based CaptureRx, a 340B technology and services organization. Terms were not disclosed. The transaction extends Pillr Health’s reach to more than 500 hospitals, health systems, and federally qualified health centers nationwide and consolidates CaptureRx’s 20-plus years of 340B expertise into Pillr’s integrated platform spanning split billing, contract pharmacy administration, entity-owned pharmacy management, referral capture, and compliance support. CEO Skip Devanny will lead the combined organization as covered entities face mounting 340B regulatory and compliance pressure. (Link)
  12. $200M Merger of Dominion Aesthetic Technologies Inc. and BellaMia Technologies Inc. Creates New Laser Device Leader Dominion Aesthetic Technologies and BellaMia Technologies have merged in a transaction valued at approximately $200 million to create a leading player in medical aesthetics laser devices. The combined company brings together complementary portfolios of energy-based devices for body contouring, skin rejuvenation, and hair removal. The merger is expected to deliver meaningful revenue and cost synergies while accelerating innovation and international expansion. Backed by strong private equity sponsorship, the new entity is well-positioned to capitalize on the continued growth of the global aesthetic medicine market. (Link)
  13. Endologix Acquires Pounce Thrombectomy System to Expand Vascular Intervention Portfolio Endologix has acquired the Pounce Thrombectomy System, a novel mechanical thrombectomy technology for arterial clot removal. The deal expands Endologix’s peripheral vascular portfolio beyond its core AAA stent graft business into the high-growth thrombectomy segment. Pounce offers a differentiated, low-profile solution for rapid clot extraction in acute limb ischemia cases. The acquisition supports Endologix’s strategy to build a more diversified vascular intervention platform and improve patient outcomes in peripheral arterial disease. (Link)
  14. Everis Medical Announces Acquisition of Hood Laboratories to Expand Head, Neck, and Airway Management Portfolio Everis Medical has acquired Hood Laboratories, a specialist in airway management and head/neck surgical products. The transaction broadens Everis’ product offering in otolaryngology and anesthesia with Hood’s established portfolio of silicone stents, tracheostomy tubes, and related airway devices. This strategic add-on enhances Everis’ position in niche ENT and airway markets while providing cross-selling opportunities across its existing customer base. The acquisition reflects continued consolidation in the fragmented medical device specialty markets. (Link)
  15. Lexitas Pharma Services Acquires Erie Retina Research and Element Erie Lexitas Pharma Services, a leading ophthalmology-focused contract research organization (CRO), has acquired Erie Retina Research (CASExERIE) and Element Erie. The transaction significantly expands Lexitas’ clinical trial capabilities in retinal diseases and strengthens its presence in the Midwest. The acquired sites bring established investigator networks, experienced staff, and a robust pipeline of ongoing retinal studies. This acquisition bolsters Lexitas’ position as a premier ophthalmology CRO amid rising demand for specialized expertise in macular degeneration, diabetic retinopathy, and other vision-threatening conditions. (Link)
  16. Midlothian Dermatology Joins Epiphany Dermatology Epiphany Dermatology, a leading physician-led dermatology practice platform, has acquired Midlothian Dermatology in Texas. The transaction expands Epiphany’s footprint in the Dallas-Fort Worth metro area and adds a well-established clinical team with strong patient loyalty. This continues Epiphany’s disciplined roll-up strategy in high-growth dermatology markets, supported by robust demand for medical, surgical, and cosmetic services. The deal reflects ongoing consolidation in the dermatology sector as independent practices seek scale, operational support, and capital for expansion. (Link)
  17. Ballantyne Plastic Surgery acquired by Alexis Miller and Gen3 Innovations Lab Aesthetics and Wellness Group, with capital partnership from New Majority Capital. Charlotte, N.C.-based Ballantyne Plastic Surgery, a 30-plus-year aesthetic practice founded by Thomas G. Liszka, M.D., has been acquired by Alexis Miller and Gen3 Innovations Lab Aesthetics and Wellness Group, with capital partnership from impact-focused investor New Majority Capital. Gen3 is an entrepreneurship-through-acquisition (ETA) search-fund vehicle targeting cash-flowing businesses with enterprise value between $5 million and $20 million. Miller, who holds an MBA from Chicago Booth and previously held roles at TikTok, Facebook, and Adobe, will serve as principal and managing partner. The acquisition continues the practice’s offerings of surgical and non-surgical aesthetic procedures in the Charlotte community. (Link)
  18. Clutch Health acquires Perx Health’s U.S. operations for undisclosed terms, marking its second healthcare acquisition. Philadelphia-based Clutch, an AI-powered retention, loyalty and engagement platform serving commerce and healthcare, has acquired the U.S. operations of digital health engagement company Perx Health. Terms were not disclosed. This is Clutch’s second healthcare acquisition, following its 2025 acquisition of Reciprocity Health. Perx’s behavioral-science-driven mobile platform — used by major U.S. health plans and provider organizations — drives medication adherence, treatment plan completion, and chronic condition self-management through gamification and personalized incentives. Perx CEO Scott Taylor will operate within Clutch Health reporting to CEO Craig Hauben, combining Perx’s engagement engine with Reciprocity’s incentive science and Clutch’s AI and data platform. (Link)
  19. Predict Health acquires the Insightin Health platform (inGAGE™) for undisclosed terms to build a unified AI solution for payer intelligence and member engagement. Arlington, Va.-based Predict Health has acquired the Insightin Health platform, an AI-powered healthcare engagement and orchestration solution serving Medicare Advantage, Medicaid, DSNP, ACA, and Commercial health plans. Financial terms were not disclosed. The combined platform will support health plans serving more than 3 million covered lives across 25 states and powers millions of member interactions annually. Predict Health leverages over 800 million healthcare and consumer data records and 300 million-plus member profiles, while the acquired inGAGE™ platform adds real-time journey orchestration, next-best-action decisioning, and omnichannel outreach across phone, text, IVR, email, direct mail, and digital channels. (Link)
  20. InSphero AG Acquires PhenoVista Biosciences Inc. to Expand Advanced 3D Cell-based Assay Capabilities InSphero AG has acquired PhenoVista Biosciences, a provider of advanced 3D cell-based assay services and imaging solutions. The transaction significantly strengthens InSphero’s position in the rapidly growing 3D microtissue and organoid market for drug discovery and toxicology. PhenoVista brings proprietary assay development expertise and high-content imaging capabilities that complement InSphero’s spheroid and organoid platform technologies. The acquisition enhances InSphero’s ability to support pharmaceutical clients with more predictive, human-relevant preclinical models.(Link)

Venture Deals and Other

  1. Century Health raises $5M Seed led by Origin Ventures with participation from InnovateHealth Ventures, 25madison, Next Play Ventures, 2048 Ventures, Alumni Ventures, and angel investor Zorba Lieberman. Century Health, a New York-based healthcare AI company, has closed an oversubscribed $5 million Seed round. The financing was led by Origin Ventures, the Chicago-based early-stage venture firm focused on the “digital native economy,” with participation from InnovateHealth Ventures, 25madison, Next Play Ventures, 2048 Ventures, Alumni Ventures, and strategic angel investors including Zorba Lieberman alongside clinician angels. The capital will fund expansion of partnerships with pharmaceutical and life sciences companies, growth of Century’s specialty provider data network, and enhancements to its AI-powered CHARM platform that converts unstructured EHR data into research-ready real-world evidence across neurology, nephrology, ophthalmology, and other specialties. (Link)
  2. Commure raises $70M at a $7B post-money valuation led by General Catalyst with participation from Sequoia Capital, Morgan Stanley, and Kirkland & Ellis. Mountain View-based Commure, the AI platform for healthcare operations, has banked $70 million in fresh financing at a $7 billion post-money valuation, taking total funding to $750 million. General Catalyst led the round with participation from Sequoia Capital, Morgan Stanley, and Kirkland & Ellis. The company, which merged with Athelas in 2023, deploys agentic AI and ambient workflow tools across more than 500 healthcare organizations and 3,000-plus care sites, including over 130 of the country’s largest health systems such as Tenet Healthcare and HCA Healthcare. Proceeds will scale its revenue cycle and practice management platform, enhance agentic AI infrastructure, and expand globally. (Link)
  3. CVRD Health raises $5M Seed led by Upfront Ventures with participation from Waterline Ventures and Distributed Ventures. CVRD Health has closed a $5 million Seed round led by Upfront Ventures, with participation from Waterline Ventures and Distributed Ventures. Upfront’s general partner Kevin Zhang highlighted CVRD’s positioning in the underserved government contracting market, where federal contracting exceeds $773 billion annually. The proceeds will fund platform development, expansion of the company’s compliance and member advocacy teams, and broader adoption among federal government contractors nationwide. CVRD modernizes benefits compliance for contractors under the Service Contract Act, Davis-Bacon Related Acts, and prevailing wage laws, pairing real-time benefit tracking with an Individual Coverage Health Reimbursement Arrangement (ICHRA) and dedicated member advocates. (Link)
  4. Kin Health raises $9M Seed led by Maveron with participation from Town Hall Ventures, Flex Capital, Eniac Ventures, The Family Fund, Pear VC, Watershed Ventures, Foundry Square Capital, and angel investors including GoodRx co-founders Doug Hirsch and Trevor Bezdek, Nabeel Quryshi, Jay Desai, Alex Cohen, and Saharsh Patel. Los Angeles-based Kin Health, a free patient-facing app that records and summarizes medical visits, has raised a $9 million Seed round led by Maveron. Participation came from Town Hall Ventures, Flex Capital, Eniac Ventures, The Family Fund, Pear VC, Watershed Ventures, Foundry Square Capital, and a deep angel roster including GoodRx co-founders Doug Hirsch and Trevor Bezdek (who join as founding partners and executive chairmen), Nabeel Quryshi, Jay Desai, Alex Cohen, Saharsh Patel, and more than 30 physicians. Funding will expand the consumer product, deepen Kin’s longitudinal health-record capability, build a clinical quality engine, and develop downstream care navigation features. (Link)
  5. Nourish raises $100M Series C led by Menlo Ventures with participation from Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, Y Combinator, BoxGroup, Atomico, Daybreak, and Operator Partners. New York-based Nourish, the largest dietitian-led metabolic health clinic in the U.S., has closed a $100 million Series C at a reported $1.75 billion post-money valuation, taking total funding to $215 million. Menlo Ventures led the round, with partner J.P. Sanday joining the board, alongside Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, Y Combinator, BoxGroup, Atomico, Daybreak, and Operator Partners. Capital will grow Nourish’s network of 10,000-plus registered dietitians, accelerate AI-agent investment for patients and providers, expand its metabolic clinic care model with GLP-1 integration, and deepen partnerships with health plans, employers, and health systems. (Link)
  6. Vi (Vi Labs) completes a $145M transaction at a $1.64B valuation with shareholders including General Atlantic, Revelstoke, 1902 Capital (managed by The Pritzker Organization), Square Peg, Savano Capital, and Island Green. New York-based Vi, the enterprise-AI platform for healthcare, life sciences, and wellness, has completed a $145 million transaction valuing the company at $1.64 billion alongside the launch of a new suite of vertically specialized AI agents. The transaction consisted of both secondary and primary capital, supporting top talent retention and acquisition, platform and new product investment, and balance sheet strengthening. The company’s shareholders include General Atlantic, Revelstoke, 1902 Capital managed by The Pritzker Organization, Square Peg, Savano Capital, Island Green and others. Vi serves 100-plus enterprise customers, supports more than 190 million lives, and has helped bring 50-plus drugs to market. (Link)
  7. cAMPfield Therapeutics Raises $180M Series A to Advance I&I Pipeline cAMPfield Therapeutics, a San Diego-based inflammation and immunology (I&I) company led by former Roivant executive Bill Gerhart, has closed a $180 million Series A financing. The round was led by Mountainfield Venture Partners with strong participation from a marquee syndicate including Novo Holdings, RA Capital, Frazier Life Sciences, Deep Track Capital, Forbion, Abingworth, Venrock, and Longitude Capital. Proceeds will be used to advance cAMPfield’s pipeline of licensed assets targeting autoimmune and inflammatory diseases, as well as support clinical development and business development activities. The substantial raise reflects continued strong investor appetite for high-quality I&I platforms in a competitive therapeutics landscape. (Link)
  8. Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology Blank Bio has closed a Seed financing round and entered a strategic collaboration with PacBio. The partnership combines Blank Bio’s AI expertise with PacBio’s long-read sequencing technology to develop advanced RNA foundation models for precision oncology. The collaboration aims to improve the discovery and development of novel RNA-based therapeutics and biomarkers by generating higher-resolution transcriptomic insights. This marks another significant step in the convergence of AI and long-read sequencing for next-generation cancer therapies. (Link)
  9. Vital Signals raises over $15M led by XYZ Ventures to transform blood pressure management. San Francisco-based Vital Signals, founded by technology veteran Tom Moss, has raised more than $15 million in funding led by XYZ Ventures to advance its consumer blood pressure and long-term cardiovascular health platform. XYZ Ventures’ Ross Fubini described the company as having achieved a “technological breakthrough previously assumed to be impossible.” Proceeds will support product development and commercialization of its consumer-facing monitoring platform ahead of a planned Series A of $50–100 million. Moss previously held leadership roles at Google, Motorola, Razer, and Skydio. The funding addresses hypertension, which affects more than 100 million Americans and is often called the “silent killer.” (Link)
Spenser Lin No Comments

Healthcare News, Deals, and Investments Update May 18th, 2026

LECO_Weekly-Healthcare-News_5-18-2026-1Download
  1. Boston Scientific Announces $1.5 billion Strategic Investment in MiRus LLC Boston Scientific Corporation (NYSE: BSX) announced a $1.5 billion strategic investment for an approximately 34% equity stake in MiRus LLC, a privately held company developing proprietary biomaterials, implants, and procedural solutions for cardiovascular and orthopedic diseases. Announced May 18, 2026, the agreement includes an exclusive option to acquire MiRus’ SIEGEL™ Balloon Expandable TAVR system, with potential additional payments of up to $3 billion upon clinical and regulatory milestones. The nickel-free, rhenium-alloy valve features a smaller delivery sheath, precise placement, and promising early clinical results in the ongoing STAR pivotal trial. The investment strengthens Boston Scientific’s interventional cardiology portfolio in the rapidly growing aortic stenosis market. (Link)
  2. J.P. Morgan, KKR, BofA Securities, and Barclays led the $478.7 million initial public offering of GMR Solutions (NYSE: GMRS) at a revised price of $15 per share GMR Solutions (NYSE: GMRS), the largest provider of emergency medical services in the U.S., priced its IPO at $15 per share, raising $478.7 million. The offering was led by a major syndicate including J.P. Morgan and KKR, with the latter also providing a $500 million concurrent private placement to bolster the company’s balance sheet. GMR Solutions plans to use the IPO proceeds primarily to pay down its existing debt. Despite the offering price being lowered from initial expectations, the IPO values the company at approximately $3.4 billion. The deal highlights significant institutional interest in the stabilization and growth potential of essential emergency and transport healthcare services. (Link)
  3. Prestige Consumer Healthcare (NYSE:PBH) Announces Acquisition of LaCorium Health Prestige Consumer Healthcare Inc. has entered into a definitive agreement to acquire LaCorium Health, a leading Australian platform in therapeutic skin care, lip, foot, and skin treatments. Announced May 13–14, 2026 alongside fiscal results, the approximately $150 million cash deal adds a high-growth, asset-light international OTC portfolio with strong market positions and expected double-digit revenue growth. The acquisition enhances Prestige’s dermatological offerings and geographic diversification. (Link)
  4. Lumexa Imaging (NASD: LMRI) executed its growth strategy by adding four new centers through joint ventures with University of Pittsburgh Medical Center (UPMC) and Advocate Health Lumexa Imaging the addition of four new locations in 2026, advancing its strategy to expand in high-growth markets via strategic partnerships. The expansion includes entry into the Pennsylvania market through a joint venture with the University of Pittsburgh Medical Center (UPMC) and further growth in the Southeast with Advocate Health. These additions, consisting of two acquisitions and two de novo centers, bring Lumexa’s total to over 190 outpatient imaging centers. The company leverages these joint ventures for capital efficiency and repeatability, focusing on the sustained shift toward outpatient, lower-cost sites of care driven by an aging population. (Link)
  5. Coastal Medical Transportation Systems Acquires Alert Ambulance to Expand New England Regional Care Network Coastal Medical Transportation Systems (CMTS), a leading privately owned medical transportation provider in New England, has completed the acquisition of Alert Ambulance Service. Announced May 18, 2026, the deal further strengthens CMTS’s position as one of the largest and most comprehensive ambulance and medical transportation providers in the region, following its prior integration of Fallon and Lifeline Ambulance Services. The acquisition expands geographic coverage across Massachusetts, New Hampshire, and Rhode Island, increases fleet size to over 325 vehicles, and grows the combined workforce to nearly 1,500 clinicians and support staff. (Link)
  6. Wellgistics Health (NASD: WGRX) Accelerates Digital Health Expansion with Planned Acquisition of WellCare Today Wellgistics Health, Inc. announced a non-binding letter of intent to acquire WellCare Today, a remote monitoring company specializing in RPM, RTM, and CCM programs powered by Samsung Galaxy Watch technology. Announced May 14, 2026, the proposed ~$15 million transaction (including $3 million cash and performance-based earnout in preferred stock) will integrate WellCare Today’s HealthAssist® platform with Wellgistics’ MSO pilot through Kare Clinicals and its network of over 6,500 independent pharmacies. The combination aims to enhance patient engagement, medication adherence, chronic care management, and reimbursement opportunities through wearable-enabled remote monitoring. (Link)
  7. Lorient Capital entered a strategic growth partnership with PeterMD to accelerate the national expansion of its proactive Medicine 3.0 healthcare platform Lorient Capital, a private equity firm exclusively focused on healthcare, has made a strategic investment in PeterMD to scale its personalized “Medicine 3.0” platform. PeterMD specializes in precision medicine, offering customized hormone health, longevity, and sexual wellness treatments through advanced diagnostics and proactive care. Lorient Capital is deploying capital from its $500 million Healthcare Fund III to fuel PeterMD’s national growth, aiming to transform the traditional reactive healthcare model. The partnership focuses on enhancing clinical outcomes and operational efficiency as PeterMD seeks to expand its footprint and bring precision-based integrated medicine to a broader national patient base. (Link)
  8. Blackstone and KKR & Co. Inc. reached a restructuring deal to take over the dental firm Affordable Care after slashing its total debt by 70% Direct lenders Blackstone and KKR are set to take control of Affordable Care, one of the largest U.S. dental services providers, following a major debt restructuring. The deal involves the lenders in a $1.4 billion private credit structure swapping their debt for equity, effectively slashing the dental firm’s debt load by approximately 70%. This restructuring provides Affordable Care with a significantly improved balance sheet to manage its extensive network of dental practices. The move underscores the increasing trend of major private credit lenders like Blackstone and KKR transitioning from creditors to equity owners to stabilize and preserve value in distressed healthcare portfolios. (Link)
  9. Quince Therapeutics (NASDAQ: QNCX)  Acquires Orphai Therapeutics and Raises up to $187 Million in Private Placement to Advance Pulmonary Pipeline Quince Therapeutics, Inc. announced the acquisition of Orphai Therapeutics, bringing in LAM-001, an inhaled formulation of rapamycin (sirolimus) for rare pulmonary diseases including pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome (BOS). Concurrently, Quince entered a private placement to raise up to $187 million ($115 million upfront + up to $72 million from warrants), led by Balyasny Asset Management with participation from a strong syndicate of healthcare investors. The combined proceeds are expected to fund operations through the end of 2028 and support multiple clinical milestones, including Phase 2 data readouts in 2027 and 2028.
  10. Orthopaedic Specialty Group and OrthoConnecticut Merge to Create Statewide Physician-Led Platform Powered by HOPCo Technology Partnership Orthopaedic Specialty Group (OSG) and OrthoConnecticut have officially merged, creating a dominant, physician-led musculoskeletal (MSK) care platform across Connecticut. The merger is bolstered by a strategic partnership with Healthcare Outcomes Performance Company (HOPCo), the global leader in MSK value-based care. While the organizations merge their clinical networks to improve patient access, HOPCo provides the digital infrastructure, including advanced analytics and care management tools, to optimize outcomes and reduce total care costs. This collaboration allows the unified practice to scale thoughtfully while preserving clinical autonomy and delivering high-quality orthopedic services closer to home for patients throughout the Connecticut. (Link)
  11. Sweetser merged with Common Ties Mental Health Services to create Maine’s largest provider of Certified Community Behavioral Health Clinic services Common Ties Mental Health Services, based in Lewiston, has officially merged with Sweetser to create a robust behavioral health network in Maine. This merger establishes Sweetser as the state’s largest provider of Certified Community Behavioral Health Clinic (CCBHC) services, integrating Common Ties’ regional expertise into Sweetser’s broad statewide platform. The investment focuses on streamlining mental health delivery, expanding free community training, and increasing access to specialized behavioral health services. By consolidating resources, the combined entity aims to build a more sustainable and accessible care model to address the rising mental health needs across Maine’s diverse and often underserved communities. (Link)
  12. Gryphon Investors-backed LEARN Behavioral acquired Little Leaves Behavioral Services from FullBloom, a portfolio company of American Securities LEARN Behavioral, a leading autism therapy provider backed by Gryphon Investors, has acquired Little Leaves Behavioral Services from FullBloom. FullBloom is a portfolio company of American Securities and sold the division to refocus on its core educational services. Little Leaves operates 18 early-intervention centers across Maryland, Virginia, and Florida, which will now join LEARN’s extensive national network. This acquisition allows LEARN Behavioral to expand its density in the Mid-Atlantic and establish a larger presence in the Florida market. The deal represents a significant consolidation within the ABA (Applied Behavior Analysis) sector, focusing on scaling early-intervention services for children with autism. (Link)
  13. Arcadea Group expanded its mission-critical software presence in Brazil through the acquisition of hemotherapy and hospital software provider Sofis Arcadea Group, a long-term investor in high-quality software firms, has acquired Sofis, a Rio de Janeiro-based provider of healthcare software. Sofis specializes in mission-critical solutions for blood bank management (hemotherapy) and hospital ERP systems, serving over 300 institutions across Brazil. This acquisition marks Arcadea’s fourth investment in the Brazilian healthcare technology market. Arcadea plans to leverage its permanent capital base to support Sofis’ long-term product development and international expansion. By transitioning from a founder-owned model to one backed by Arcadea’s global resources, Sofis aims to modernize its platform and deepen its penetration into the complex Latin American healthcare technology landscape. (Link)
  14. Iterative Health Acquires Cardiology Research Sites from NextStage Clinical Research Iterative Health, a healthcare technology and services company focused on accelerating clinical research, has acquired three cardiology research sites from NextStage Clinical Research in Texas (Beaumont, Port Arthur, and Waco). Announced on May 14, 2026, with Bourne Partners serving as financial advisor, the deal expands Iterative Health’s elite site network and strengthens its capabilities in cardiovascular research — a therapeutic area affecting nearly half of U.S. adults. The sites bring experienced teams, strong community provider connections, and an active trial portfolio, enhancing patient access to innovative therapies while providing sponsors with high-performing, real-world research centers. (Link)
  15. HealthScape Advisors Acquires PayerAlly to Strengthen Pharmacy Benefit Management Capabilities HealthScape Advisors, a leading payer advisory firm and a Chartis company, has acquired PayerAlly, an independent pharmacy consulting firm specializing in pharmacy benefit management (PBM) strategy, procurement, and optimization. Announced May 12, 2026 (with coverage extending through mid-May), the deal enhances HealthScape’s ability to help health plans and employers address rapidly rising prescription drug costs through integrated, clinically informed total cost-of-care solutions. PayerAlly’s expertise in PBM strategy complements HealthScape’s broader payer advisory platform, supporting more effective management of one of healthcare’s fastest-growing expense categories. (Link)
  16. NeuroVision Acquires Durin Life Sciences to Advance Neurodegenerative Diagnostics NeuroVision, a diagnostics company developing early detection tools for Alzheimer’s and other neurodegenerative diseases, has acquired Durin Life Sciences, a fellow diagnostics developer. Announced May 15, 2026, the deal adds Durin’s blood-based Duritect™ tests for early detection and monitoring of Alzheimer’s, Parkinson’s, and ALS. The combination accelerates NeuroVision’s platform for earlier, more accessible diagnosis and disease management, addressing critical gaps in neurodegenerative care. (Link)
  17. IKS Health Acquires ARAI Solutions to Accelerate Agentic AI Capabilities IKS Health, a global leader in care enablement and AI-driven clinical solutions, has acquired ARAI Solutions, a specialized AI management and technology company focused on biomedical knowledge graphs and clinical reasoning infrastructure. Announced May 13–14, 2026, the deal enhances IKS Health’s ability to build proprietary small language models and agentic AI systems for clinical, operational, and revenue cycle workflows. ARAI’s ontology layer and applied research expertise will improve the reliability, auditability, and efficiency of IKS’s AI platforms serving health systems nationwide. (Link)
  18. Signant Health Acquires Ametris to Create End-to-End eCOA and Digital Outcome Measures Platform Signant Health, a leading evidence generation company for clinical trials, has acquired Ametris (formerly ActiGraph), a global digital health solutions provider specializing in wearable-derived clinical outcome measures. The deal integrates Signant’s eCOA (electronic Clinical Outcome Assessment) solutions with Ametris’ validated sensor-based technologies for objective measurement of physical activity and function. The combined platform will deliver multimodal evidence—patient-reported outcomes alongside continuous real-world data—simplifying complex trials, accelerating insights, and strengthening regulatory submissions, particularly in CNS and other therapeutic areas. (Link)
  19. iSpecimen Inc. (NASD: ISPC) Secures $2.5 Million Private Placement to Support Operations Amid 89% Annual Stock Decline iSpecimen Inc. finalized a $2.5 million private placement on May 11, 2026, to bolster working capital. The biospecimen marketplace provider, currently valued at $3.39 million, has seen its share price plummet 89% over the past year to $4.57. This funding follows a $5.5 million raise in late 2025, aimed at mitigating rapid cash burn. iSpecimen, which connects medical researchers with specimen providers, will use the proceeds for general corporate purposes as it navigates significant financial challenges and seeks to stabilize its market position. (Link)
  20. Blue Sea Capital supported One Physics in its strategic acquisition and partnership with Petrone Associates to expand its Northeast clinical services footprint One Physics, the largest outsourced medical physics services company in North America, has announced its 22nd acquisition with the addition of New York-based Petrone Associates. This strategic move, backed by growth-oriented private equity firm Blue Sea Capital, significantly strengthens One Physics’ presence in the New York City metropolitan market and Northern New Jersey. The partnership leverages One Physics’ national scale and Petrone’s established clinical reputation to provide comprehensive diagnostic and therapy medical physics, radiation safety, and dosimetry services. Blue Sea Capital, managing over $1.5 billion in assets, remains committed to accelerating One Physics’ industry leadership through continued regional consolidation. (Link)

Venture Deals and Other

  1. Sound Ventures, Alumni Ventures, Link Ventures, Redesign Health, and RRE Ventures invested $17 million in Anomaly Insights to address healthcare payer-provider information asymmetry. Anomaly Insights, an AI-powered payer intelligence firm, secured $17 million in funding led by Sound Ventures to combat the informational gap between healthcare payers and providers. The investment includes participation from RRE Ventures and Redesign Health, focusing on Anomaly’s real-time AI platform that identifies and corrects billing errors and payment inaccuracies. The company aims to reduce the massive administrative waste in the U.S. healthcare system by providing transparency in the claims process. This new capital will be used to enhance Anomaly’s machine learning models and scale its solutions across larger health systems and insurance networks to streamline payment cycles. (Link)
  2. McKesson Ventures, FCA Venture Partners, Sanofi Ventures, and AIX Ventures led a $26 million Series A for Branchlab to scale its AI-driven biopharma commercialization platform Branchlab raised $26 million in a Series A round led by McKesson Ventures to accelerate the growth of its Pathwai™ platform. The round, which included corporate venture backing from Sanofi Ventures, brings Branchlab’s total funding to $35 million. The company uses privacy-first AI to optimize the patient journey and enhance pharmaceutical commercialization, reporting a 70% increase in patient activation efficiency. Branchlab intends to use the capital to expand its engineering and data science teams in New York and Colorado. By providing real-time insights to biopharma brands, Branchlab aims to make pharmaceutical marketing more effective and patient-centric through advanced data analytics. (Link)
  3. AIX Ventures led a $2 million pre-Seed funding round for Chromie Health to develop its autonomous AI-powered hospital workforce management platform Chromie Health, a New York-based startup, secured $2 million in pre-Seed funding led by AIX Ventures to tackle the hospital staffing crisis. The company develops autonomous AI agents that automate complex administrative tasks and workforce scheduling without requiring deep IT integration. Chromie Health’s platform is designed to alleviate the burnout of clinical staff by handling the logistics of hospital operations through intelligent automation. The investment will support the development of additional “digital agents” capable of reasoning through clinical context and staffing needs. This seed capital positions Chromie Health to pilot its solutions across more health systems seeking to modernize their operational efficiency. (Link)
  4. Blueprint Equity, Villain Capital, Z21 Ventures, and Bienville Capital led a $14 million growth funding round for pediatric-focused AI operating system Develo Develo, an AI-native operating system for pediatric practices, raised $14 million in a funding round led by Blueprint Equity. The platform integrates clinical workflows, billing, and parent engagement into a single AI-driven ecosystem, currently serving hundreds of providers across 25 states. The capital will be used to accelerate the development of specialized AI tools, including automated charge capture and AI-assisted scribing for pediatricians. Develo aims to reduce the administrative burden that leads to physician burnout while improving the financial performance of independent pediatric practices. The investment highlights a growing trend toward specialty-specific AI platforms that address unique clinical and operational workflows. (Link)
  5. Thrive Capital, General Catalyst, Accel, Bain Capital Ventures, Redpoint, BoxGroup, and Pear VC backed Forus with $160 million to build its AI-powered pharmaceutical delivery network Forus, formerly known as Tandem, raised $160 million in a major funding round backed by top-tier venture firms including Thrive Capital and General Catalyst. The company is building an AI-powered infrastructure that connects doctors, pharmacies, and biopharma companies to streamline the drug fulfillment process. Forus automates the “last-mile” clinical steps, such as insurance authorizations, to ensure patients receive treatments faster. With five of the top ten global biopharma companies already utilizing the network, Forus plans to use the investment to expand its nationwide reach and further integrate its AI layer into existing physician and pharmacy workflows to eliminate treatment delays. (Link)
  6. Uncork Capital, Frist Cressey Ventures, Moxxie Ventures, and Coalition Operators provided $11.6 million in Seed funding for the launch of Knit Health’s clinical behavior AI Knit Health, a spin-out from UC Berkeley, launched with $11.6 million in Seed funding co-led by Uncork Capital and Frist Cressey Ventures. The company is developing a Large Clinical Behavior Model (LCBM) trained on real-world clinician decisions across 30 U.S. health systems. Knit Health’s AI agents are designed to handle triage, patient flow, and care coordination by learning from collective clinical experience rather than just static text. The funding will be used to scale its foundational intelligence layer and deploy AI agents that assist in high-stakes hospital environments. This investment reflects a shift toward “Action AI” that can reason and perform complex tasks in clinical settings. (Link)
  7. Salesforce Ventures, Echo Health Ventures, Susa Ventures, Matrix Partners, and HC9 Ventures raised $17.5 million in Series A funding for Optura’s AI governance platform Optura, a Nashville-based healthcare AI governance platform, secured $17.5 million in Series A funding led by Salesforce Ventures. The investment, which brings Optura’s total funding to $25 million, will support the expansion of its “Return on AI Investment” (ROAI) platform. Optura helps enterprise healthcare organizations, such as Independence Blue Cross, map fragmented data and measure the efficacy of their AI agents. The capital will be used to scale partnerships with LLM providers and grow its engineering teams. By providing a unified knowledge layer, Optura enables healthcare leaders to prioritize AI use cases based on actual operational readiness and projected business value. (Link)
  8. Norwest, Primary, Next Ventures, Constellation, and Scrub Capital led a $25 million financing round for Tokaido Health to launch its AI medication steerage platform. Tokaido Health emerged from stealth with $25 million in funding led by Norwest and Primary to address skyrocketing pharmacy costs for employers. The platform utilizes AI and behavioral economics to identify same-or-better medications that cost less, steering members toward high-value options like biosimilars. Tokaido layers on top of existing PBM stacks, allowing for a seamless integration without plan redesigns. The investment will be used to scale its concierge-style member outreach and expand its clinical reasoning engine. By focusing on site-of-care steerage and polypharmacy reconciliation, Tokaido aims to eliminate billions in wasted drug spending while improving the patient experience. (Link)
  9. Andera Partners, American Century Investments, Clarevia Ventures, Time BioVentures, View Ventures, Cadence Healthcare Ventures, and Anduril Investors led a $20 million Series D for Rivermark Medical Rivermark Medical, a urology-focused medical device company, raised $20 million in Series D funding led by Andera Partners. The financing will support the ongoing RAPID III pivotal clinical trial for the FloStent™ System, a non-surgical treatment for men with benign prostatic hyperplasia (BPH). The investment syndicate includes American Century Investments and Time BioVentures, focusing on bringing this reversible, office-based therapy to market. The FloStent is designed to be easily adjustable and tissue-preserving, offering a first-line alternative to more invasive surgical procedures. The capital will also be used to prepare for a U.S. commercial launch following expected regulatory approval. (Link)
  10. Aulis Capital led a $13.4 million Seed funding round for Shyld AI to accelerate the deployment of its autonomous AI-driven infection control solutions Shyld AI, a healthcare technology company, secured $13.4 million in Seed funding led by Aulis Capital to expand its active intelligence solutions for hospital facilities. Shyld AI develops autonomous physical agents that use AI and UV disinfection to reduce environmental contamination in high-risk areas like operating rooms. The funding will accelerate deployments across U.S. health systems and support the company’s expansion into regulated pharmaceutical manufacturing environments. By streamlining infection control and compliance without adding to the workload of hospital staff, Shyld AI aims to improve patient safety and operational efficiency. The investment marks a significant milestone in the adoption of autonomous hygiene agents in healthcare. (Link)

Sign up for all the Lawrence, Evans & Co., LLC news and activities
CLICK HERE